STOCK TITAN

InspireMD Q3 loss narrows to $9.76M as revenue falls

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

InspireMD, Inc. (NSPR) reported third-quarter 2026 revenue of $2.242 million, versus $2.523 million a year earlier; gross profit was $240,000 versus $864,000, while net loss narrowed to $9.762 million from $12.708 million. For the first nine months, revenue was $7.411 million versus $5.830 million and net loss was $37.775 million versus $37.025 million. Operating cash use was $33.860 million versus $25.758 million.

Cash was $19.246 million as of September 30, 2026. The company disclosed substantial doubt about its ability to continue as a going concern, stating it lacked resources to fund operations for at least 12 months from issuance; it closed a November offering on November 16 for approximately $37.5 million in gross proceeds, before discounts, commissions and estimated expenses. The FDA approved CGuard Prime 80 cm on November 9. By September 30, all affected CGuard Prime 135 cm products in the voluntary U.S. recall had been returned and customer credits issued; the company recorded approximately $734,000 in revenue reductions and $612,000 of inventory impairment. It had a 180-calendar-day period, through January 13, 2027, to regain Nasdaq minimum bid-price compliance.

3 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 5 points

How the balance works

Positive

  • Moderate pointNine-month revenue: $7.411 million, versus $5.830 million.
  • Moderate pointThird-quarter net loss: $9.762 million, versus $12.708 million.
  • Minor pointCGuard Prime 80 cm received FDA approval on November 9, 2026.

Negative

  • Major pointGoing-concern doubt: insufficient resources for at least 12 months.
  • Moderate pointThird-quarter revenue: $2.242 million, versus $2.523 million.
  • Moderate pointNine-month operating cash use: $33.860 million, versus $25.758 million.
  • Moderate pointNasdaq bid-price compliance deadline: January 13, 2027.
  • Moderate pointRecall impact: $734,000 revenue reduction and $612,000 inventory impairment.

Filing Explained

The lower exercise price leaves potential share issuance contingent on exercise; the amendments did not themselves issue shares.

On September 21, 2026, the company amended warrants covering 14,315,927 shares, reducing the exercise price from $1.3827 to $0.7674; this changes potential issuance terms, not a report of shares issued through the amendment. It reports 47,119,438 common shares outstanding at September 30, 2026 and 54,127,439 on the November 16, 2026 cover, a higher reported share count by the filing date.

If exercised, the amended warrants would add shares and reduce existing holders’ percentage ownership. Separately, 42,188,078 pre-funded warrants were outstanding at September 30; these convert into shares when exercised.

Following the November 12, 2026 FDA-approval announcement, the amended warrants are set to expire December 11, 2026 unless exercised earlier. The unamended Series K warrants expired unexercised on October 28, 2026.

Third-quarter revenue $2.242 million (2026); $2.523 million (2025) Three months ended September 30
Nine-month revenue $7.411 million (2026); $5.830 million (2025) Nine months ended September 30
Third-quarter gross profit $240,000 (2026); $864,000 (2025) Three months ended September 30
Third-quarter net loss $9.762 million (2026); $12.708 million (2025) Three months ended September 30
Nine-month net loss $37.775 million (2026); $37.025 million (2025) Nine months ended September 30
Net cash used in operating activities $33.860 million (2026); $25.758 million (2025) Nine months ended September 30
Cash and cash equivalents $19.246 million As of September 30, 2026
Gross offering proceeds Approximately $37.5 million November 2026 offering closed November 16, 2026; before discounts, commissions and estimated offering expenses
going concern financial
"substantial doubt about the Company’s ability to continue as a going concern"
Going concern is the accounting assumption that a company will keep operating and meeting its obligations for the foreseeable future. The phrase matters most when a company or its auditors disclose substantial doubt about it, a formal warning that the business may not have enough resources to continue without raising money, restructuring, or selling assets. That language in a filing or press release signals elevated financial risk.
premarket approval regulatory
"submitted a premarket approval (PMA) to the U.S. Food and Drug Administration"
Premarket approval is the formal regulatory clearance required before certain medical devices can be sold, based on detailed evidence that the product is safe and effective. For investors, it’s a major milestone because receiving approval typically clears the way for commercial sales and reduces regulatory uncertainty, while failure or delays can block revenue and raise the risk profile; think of it like a safety certificate needed before a new car model can be sold.
full ratchet anti-dilution adjustment financial
"Pursuant to the full ratchet anti-dilution adjustment provisions"
pre-funded warrants financial
"there were 42,188,078 outstanding pre-funded warrants"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
Medical Device Regulation regulatory
"CE Mark recertification for CGuard EPS under the EU Medical Device Regulation"
Rules and processes governments require for making, testing, approving, and monitoring medical devices so they are safe and work as intended. Think of it like a building code and inspection process for devices: meeting these rules can be costly and slow but opens markets and reduces the risk of recalls and legal trouble, while failure to comply can cut revenue, delay product launches, or cause fines—issues investors watch closely.
fair value hierarchy financial
"the fair value hierarchy that prioritizes observable and unobservable inputs"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were NSPR’s third-quarter 2026 results?

NSPR reported Q3 2026 revenue of $2.242 million, versus $2.523 million a year earlier, and gross profit of $240,000 versus $864,000. Net loss narrowed to $9.762 million from $12.708 million.

Why did NSPR report substantial doubt about its ability to continue as a going concern?

InspireMD said its accumulated deficit, recurring losses, negative operating cash flows and current cash position left it without sufficient resources to fund operations for at least 12 months from issuance of the statements. Separately, it closed a November offering for approximately $37.5 million in gross proceeds on November 16, 2026.

What does NSPR need to do to regain Nasdaq bid-price compliance?

The company’s compliance period ran through January 13, 2027. To regain compliance, its common stock needed a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days.

Why was InspireMD’s CGuard Prime 135 cm recalled?

During a controlled launch, InspireMD determined that the delivery system’s technical success rate did not meet performance expectations. The voluntary U.S. recall was initiated in consultation with the FDA and was limited to the delivery system; the CGuard stent implant was not involved.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false Q3 --12-31 0001433607 0001433607 2026-01-01 2026-09-30 0001433607 2026-11-16 0001433607 2026-09-30 0001433607 2025-12-31 0001433607 us-gaap:SeriesCPreferredStockMember 2026-09-30 0001433607 us-gaap:SeriesCPreferredStockMember 2025-12-31 0001433607 2026-07-01 2026-09-30 0001433607 2025-07-01 2025-09-30 0001433607 2025-01-01 2025-09-30 0001433607 us-gaap:CommonStockMember 2024-12-31 0001433607 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2024-12-31 0001433607 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001433607 us-gaap:RetainedEarningsMember 2024-12-31 0001433607 2024-12-31 0001433607 us-gaap:CommonStockMember 2025-06-30 0001433607 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2025-06-30 0001433607 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001433607 us-gaap:RetainedEarningsMember 2025-06-30 0001433607 2025-06-30 0001433607 us-gaap:CommonStockMember 2025-12-31 0001433607 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2025-12-31 0001433607 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001433607 us-gaap:RetainedEarningsMember 2025-12-31 0001433607 us-gaap:CommonStockMember 2026-06-30 0001433607 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2026-06-30 0001433607 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001433607 us-gaap:RetainedEarningsMember 2026-06-30 0001433607 2026-06-30 0001433607 us-gaap:CommonStockMember 2025-01-01 2025-09-30 0001433607 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2025-01-01 2025-09-30 0001433607 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-09-30 0001433607 us-gaap:RetainedEarningsMember 2025-01-01 2025-09-30 0001433607 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0001433607 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2025-07-01 2025-09-30 0001433607 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0001433607 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001433607 us-gaap:CommonStockMember 2026-01-01 2026-09-30 0001433607 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2026-01-01 2026-09-30 0001433607 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-09-30 0001433607 us-gaap:RetainedEarningsMember 2026-01-01 2026-09-30 0001433607 us-gaap:CommonStockMember 2026-07-01 2026-09-30 0001433607 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2026-07-01 2026-09-30 0001433607 us-gaap:AdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0001433607 us-gaap:RetainedEarningsMember 2026-07-01 2026-09-30 0001433607 us-gaap:CommonStockMember 2025-09-30 0001433607 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2025-09-30 0001433607 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001433607 us-gaap:RetainedEarningsMember 2025-09-30 0001433607 2025-09-30 0001433607 us-gaap:CommonStockMember 2026-09-30 0001433607 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2026-09-30 0001433607 us-gaap:AdditionalPaidInCapitalMember 2026-09-30 0001433607 us-gaap:RetainedEarningsMember 2026-09-30 0001433607 2026-11-16 2026-11-16 0001433607 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2026-09-30 0001433607 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2026-09-30 0001433607 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2026-09-30 0001433607 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member us-gaap:MoneyMarketFundsMember 2026-09-30 0001433607 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2025-12-31 0001433607 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2025-12-31 0001433607 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2025-12-31 0001433607 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member us-gaap:MoneyMarketFundsMember 2025-12-31 0001433607 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2025-12-31 0001433607 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2025-12-31 0001433607 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2025-12-31 0001433607 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2025-12-31 0001433607 us-gaap:OneTimeTerminationBenefitsMember 2026-01-01 2026-09-30 0001433607 us-gaap:ContractTerminationMember 2026-01-01 2026-09-30 0001433607 us-gaap:OneTimeTerminationBenefitsMember 2026-07-01 2026-09-30 0001433607 us-gaap:ContractTerminationMember 2026-07-01 2026-09-30 0001433607 NSPR:PreferredStockBlankCheckMember 2026-09-30 0001433607 us-gaap:SeriesCPreferredStockMember 2026-01-01 2026-09-30 0001433607 us-gaap:SeriesCPreferredStockMember srt:MaximumMember 2026-09-30 0001433607 us-gaap:SeriesCPreferredStockMember srt:MinimumMember 2026-09-30 0001433607 NSPR:PreFundedWarrantsMember 2026-09-30 0001433607 NSPR:SeriesJWarrantsMember 2026-09-21 0001433607 NSPR:SeriesKWarrantsMember 2026-09-21 0001433607 us-gaap:WarrantMember srt:MaximumMember 2026-09-21 0001433607 us-gaap:WarrantMember srt:MinimumMember 2026-09-21 0001433607 NSPR:PreFundedWarrantsMember 2026-09-21 0001433607 us-gaap:WarrantMember 2026-09-30 0001433607 NSPR:SeriesKWarrantsMember 2026-11-12 0001433607 NSPR:SeriesGWarrantsMember 2026-01-01 2026-09-30 0001433607 us-gaap:RestrictedStockMember NSPR:EmployeesAndDirectorsMember 2026-01-01 2026-09-30 0001433607 us-gaap:RestrictedStockUnitsRSUMember srt:ChiefExecutiveOfficerMember 2026-01-01 2026-09-30 0001433607 us-gaap:EmployeeStockOptionMember srt:ChiefExecutiveOfficerMember 2026-01-01 2026-09-30 0001433607 NSPR:SeriesJWarrantsMember NSPR:AmendedWarrantsMember 2026-09-30 0001433607 NSPR:SeriesKWarrantsMember NSPR:AmendedWarrantsMember 2026-09-30 0001433607 NSPR:AmendedWarrantsMember 2026-09-30 0001433607 NSPR:AmendedWarrantsMember 2026-01-01 2026-09-30 0001433607 NSPR:SeriesJWarrantsMember NSPR:UnamendedWarrantsMember 2026-09-30 0001433607 NSPR:SeriesKWarrantsMember NSPR:UnamendedWarrantsMember 2026-09-30 0001433607 NSPR:UnamendedWarrantsMember 2026-09-30 0001433607 NSPR:UnamendedWarrantsMember 2026-01-01 2026-09-30 0001433607 NSPR:SeriesJWarrantsMember 2026-09-30 0001433607 NSPR:SeriesKWarrantsMember 2026-09-30 0001433607 srt:ChiefExecutiveOfficerMember 2025-07-01 2025-09-30 0001433607 srt:ChiefExecutiveOfficerMember 2025-01-01 2025-09-30 0001433607 us-gaap:SeriesCPreferredStockMember 2025-01-01 2025-09-30 0001433607 us-gaap:SeriesCPreferredStockMember 2026-07-01 2026-09-30 0001433607 us-gaap:SeriesCPreferredStockMember 2025-07-01 2025-09-30 0001433607 country:US 2026-01-01 2026-09-30 0001433607 country:DE 2026-07-01 2026-09-30 0001433607 country:DE 2025-07-01 2025-09-30 0001433607 country:DE 2026-01-01 2026-09-30 0001433607 country:DE 2025-01-01 2025-09-30 0001433607 country:IT 2026-07-01 2026-09-30 0001433607 country:IT 2025-07-01 2025-09-30 0001433607 country:IT 2026-01-01 2026-09-30 0001433607 country:IT 2025-01-01 2025-09-30 0001433607 country:PL 2026-07-01 2026-09-30 0001433607 country:PL 2025-07-01 2025-09-30 0001433607 country:PL 2026-01-01 2026-09-30 0001433607 country:PL 2025-01-01 2025-09-30 0001433607 country:US 2026-07-01 2026-09-30 0001433607 country:US 2025-07-01 2025-09-30 0001433607 country:US 2025-01-01 2025-09-30 0001433607 NSPR:OtherCountriesMember 2026-07-01 2026-09-30 0001433607 NSPR:OtherCountriesMember 2025-07-01 2025-09-30 0001433607 NSPR:OtherCountriesMember 2026-01-01 2026-09-30 0001433607 NSPR:OtherCountriesMember 2025-01-01 2025-09-30 0001433607 NSPR:CustomerAMember NSPR:SaleMember us-gaap:CustomerConcentrationRiskMember 2026-07-01 2026-09-30 0001433607 NSPR:CustomerAMember NSPR:SaleMember us-gaap:CustomerConcentrationRiskMember 2025-07-01 2025-09-30 0001433607 NSPR:CustomerAMember NSPR:SaleMember us-gaap:CustomerConcentrationRiskMember 2026-01-01 2026-09-30 0001433607 NSPR:CustomerAMember NSPR:SaleMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-09-30 0001433607 NSPR:CustomerBMember NSPR:SaleMember us-gaap:CustomerConcentrationRiskMember 2026-07-01 2026-09-30 0001433607 NSPR:CustomerBMember NSPR:SaleMember us-gaap:CustomerConcentrationRiskMember 2025-07-01 2025-09-30 0001433607 NSPR:CustomerBMember NSPR:SaleMember us-gaap:CustomerConcentrationRiskMember 2026-01-01 2026-09-30 0001433607 NSPR:CustomerBMember NSPR:SaleMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-09-30 0001433607 NSPR:ResearchAndDevelopmentMember 2026-07-01 2026-09-30 0001433607 NSPR:ResearchAndDevelopmentMember 2025-07-01 2025-09-30 0001433607 NSPR:ResearchAndDevelopmentMember 2026-01-01 2026-09-30 0001433607 NSPR:ResearchAndDevelopmentMember 2025-01-01 2025-09-30 0001433607 us-gaap:SellingAndMarketingExpense 2026-07-01 2026-09-30 0001433607 us-gaap:SellingAndMarketingExpense 2025-07-01 2025-09-30 0001433607 us-gaap:SellingAndMarketingExpense 2026-01-01 2026-09-30 0001433607 us-gaap:SellingAndMarketingExpense 2025-01-01 2025-09-30 0001433607 us-gaap:GeneralAndAdministrativeExpense 2026-07-01 2026-09-30 0001433607 us-gaap:GeneralAndAdministrativeExpense 2025-07-01 2025-09-30 0001433607 us-gaap:GeneralAndAdministrativeExpense 2026-01-01 2026-09-30 0001433607 us-gaap:GeneralAndAdministrativeExpense 2025-01-01 2025-09-30 0001433607 us-gaap:SubsequentEventMember NSPR:November2026OfferingMember 2026-10-01 2026-11-13 0001433607 us-gaap:SubsequentEventMember NSPR:November2026PreFundedWarrantsMember 2026-11-13 0001433607 us-gaap:SubsequentEventMember NSPR:November2026PreFundedWarrantsMember NSPR:SeriesLWarrantsMember 2026-11-13 0001433607 us-gaap:SubsequentEventMember NSPR:SeriesLWarrantsMember 2026-11-13 0001433607 us-gaap:SubsequentEventMember NSPR:November2026PreFundedWarrantsMember NSPR:SeriesLWarrantsMember srt:MinimumMember 2026-11-13 0001433607 us-gaap:SubsequentEventMember NSPR:November2026OfferingMember NSPR:SeriesLWarrantsMember 2026-11-16 2026-11-16 0001433607 us-gaap:SubsequentEventMember NSPR:November2026PreFundedWarrantsMember NSPR:SeriesLWarrantsMember srt:MinimumMember 2026-11-16 0001433607 us-gaap:SubsequentEventMember NSPR:November2026PreFundedWarrantsMember srt:MaximumMember NSPR:SeriesLWarrantsMember 2026-11-16 2026-11-16 0001433607 us-gaap:SubsequentEventMember NSPR:November2026PreFundedWarrantsMember srt:MaximumMember NSPR:SeriesLWarrantsMember 2026-11-16 0001433607 us-gaap:SubsequentEventMember NSPR:November2026PreFundedWarrantsMember srt:MinimumMember us-gaap:SeriesCPreferredStockMember 2026-11-13 0001433607 us-gaap:SubsequentEventMember NSPR:November2026PreFundedWarrantsMember srt:MaximumMember us-gaap:SeriesCPreferredStockMember 2026-11-13 0001433607 us-gaap:SubsequentEventMember NSPR:November2026PreFundedWarrantsMember srt:MaximumMember us-gaap:SeriesCPreferredStockMember 2026-11-13 2026-11-13 0001433607 us-gaap:SubsequentEventMember NSPR:November2026PreFundedWarrantsMember us-gaap:SeriesCPreferredStockMember 2026-11-13 2026-11-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure NSPR:Integer

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended: September 30, 2026

 

OR

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from to

 

Commission file number: 001-35731

 

InspireMD, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   26-2123838
(State or other jurisdiction of   (I.R.S. Employer
incorporation or organization)   Identification No.)

 

6303 Waterford District Drive

Suite 215

Miami, Florida 33126

(Address of principal executive offices)

(Zip Code)

 

(888) 776-6804

(Registrant’s telephone number, including area code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☒ Smaller reporting company ☒
  Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001 per share   NSPR   Nasdaq Capital Market

 

The number of shares of the registrant’s common stock, $0.0001 par value per share, outstanding as of November 16, 2026: 54,127,439

 

 

 

 
 

 

PART I – FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

INSPIREMD, INC.

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

AS OF AND FOR THE QUARTER ENDED SEPTEMBER 30, 2026

 

TABLE OF CONTENTS

 

  Page
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED):  
Condensed Consolidated Balance Sheets F-2 - F-3
Condensed Consolidated Statements of Operations F-4
Condensed Consolidated Statements of Changes in Equity F-5 - F-8
Condensed Consolidated Statements of Cash Flows F-9
Notes to the Condensed Consolidated Financial Statements F-10 - F-19

 

F-1

 

 

INSPIREMD, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(U.S. dollars in thousands, except share and per share data)

 

   September 30,   December 31, 
   2026   2025 
ASSETS          
CURRENT ASSETS:          
Cash and cash equivalents  $19,246   $8,939 
Marketable securities   -    45,272 
Accounts receivable:          
Trade, net   1,895    2,168 
Other   444    400 
Prepaid expenses   1,077    1,296 
Inventory   2,991    3,396 
TOTAL CURRENT ASSETS   25,653    61,471 
           
NON-CURRENT ASSETS:          
Long-term deposit   455    442 
Property, plant and equipment, net   3,947    3,584 
Operating lease right-of-use assets   2,254    2,758 
Fund in respect of employee rights upon retirement   1,259    1,149 
TOTAL NON-CURRENT ASSETS   7,915    7,933 
TOTAL ASSETS  $33,568   $69,404 

 

F-2

 

 

INSPIREMD, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(U.S. dollars in thousands except share and per share data)

 

   September 30,   December 31, 
   2026   2025 
LIABILITIES AND EQUITY          
           
CURRENT LIABILITIES:          
Accounts payable and accruals:          
Trade   1,562    1,255 
Other   7,007    9,457 
TOTAL CURRENT LIABILITIES   8,569    10,712 
           
LONG-TERM LIABILITIES:          
Operating lease liabilities net of current maturities   1,711    2,224 
Liability for employee rights upon retirement and others   1,536    1,267 
           
TOTAL LONG-TERM LIABILITIES   3,247    3,491 
           
TOTAL LIABILITIES   11,816    14,203 
COMMITMENTS AND CONTINGENT LIABILITIES   -     -  
EQUITY:          
           
Common stock, par value $0.0001 per share; 250,000,000 and 150,000,000 shares authorized at September 30, 2026 and December 31, 2025; 47,119,438 and 43,532,281 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively   5    4 
Preferred C shares, par value $0.0001 per share;
1,172,000 shares authorized at September 30, 2026 and December 31, 2025; 1,718 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively
   -*    -* 
Additional paid-in capital   361,814    357,489 
Accumulated deficit   (340,067)   (302,292)
Total equity   21,752    55,201 
Total liabilities and equity  $33,568   $69,404 

 

*Represents an amount less than $1 thousand

 

The accompanying notes are an integral part of the condensed consolidated financial statements.

 

F-3

 

 

INSPIREMD, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(U.S. dollars in thousands, except share and per share data)

 

   2026   2025   2026   2025 
  

Three months ended

September 30,

  

Nine months ended

September 30,

 
   2026   2025   2026   2025 
                 
REVENUES  $2,242   $2,523   $7,411   $5,830 
COST OF REVENUES   2,002    1,659    7,258    4,361 
GROSS PROFIT   240    864    153    1,469 
OPERATING EXPENSES:                    
Research and development   3,273    3,635    12,331    11,528 
Selling and marketing   2,394    4,392    12,795    11,314 
General and administrative   3,452    5,888    12,329    16,157 
Restructuring and other   1,074    -    1,074    - 
Total operating expenses   10,193    13,915    38,529    38,999 
LOSS FROM OPERATIONS   (9,953)   (13,051)   (38,376)   (37,530)
FINANCIAL INCOME, net:   191    343    601    505 
NET LOSS  $(9,762)  $(12,708)  $(37,775)  $(37,025)
NET LOSS PER SHARE - basic and diluted  $(0.12)  $(0.17)  $(0.45)  $(0.64)
WEIGHTED AVERAGE NUMBER OF COMMON STOCK USED IN COMPUTING NET LOSS PER SHARE - basic and diluted   85,616,203    73,466,501    84,701,615    58,245,368 

 

The accompanying notes are an integral part of the condensed consolidated financial statements.

 

F-4

 

 

INSPIREMD, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

(Unaudited)

(U.S. dollars in thousands, except share data)

 

   Shares   Amount   Shares   Amount   capital   deficit   equity 
   Common stock   Preferred C
shares
   Additional paid-in   Accumulated   Total 
   Shares   Amount   Shares   Amount   capital   deficit   equity 
                             
BALANCE AT January 1, 2025   26,611,033    3    1,718    -*   289,589    (253,506)   36,086 
Net loss                            (37,025)   (37,025)
Exercise of pre-funded warrants**   2,381,651    -*    -     -          -     -* 
Issuance of common stock, included at the market offering and pre-funded warrants net of $3,148 issuance costs   7,510,293    1    -     -     38,713    -     38,714 
Exercise of Warrants Series I to 10,561,685 pre-funded warrants and 2,352,393 common stock, net of $1,000 issuance costs   2,352,393    -*    -     -     16,855    -     16,855 
Share-based compensation related to restricted stock, restricted stock units and stock option awards, net of forfeitures of 322,919 shares   3,063,771    -*    -     -     9,484    -     9,484 
BALANCE AT September 30, 2025   41,919,141    4    1,718    -*    354,641    (290,531)   64,114 

 

*Represents an amount less than $1 thousand
**Prior to June 30, 2025, pre-funded warrants were exercised on a cashless basis; from July 1, 2025 through September 30, 2025, pre-funded warrants were exercised for cash.

 

The accompanying notes are an integral part of the condensed consolidated financial statements.

 

F-5

 

 

INSPIREMD, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

(Unaudited)

(U.S. dollars in thousands, except share data)

 

   Shares   Amount   Shares   Amount   capital   deficit   equity 
   Common stock   Preferred C
shares
   Additional paid-in   Accumulated   Total 
   Shares   Amount   Shares   Amount   capital   deficit   equity 
                             
BALANCE AT July 1, 2025   32,552,888    3    1,718    -*    298,063    (277,823)   20,243 
Net loss                            (12,708)   (12,708)
Exercise of pre-funded warrants**   970,098    -*    -     -     -     -     -* 
Exercise of Warrants Series I to 10,561,685 pre-funded warrants and 943,641 common stock, net of $891 issuance costs   943,641    -*    -     -     15,017    -     15,017 
Issuance of common stock, included at the market offering and 9,764,804 pre-funded warrants net of $3,126 issuance costs   7,236,672    1    -     -     38,017    -     38,018 
Share-based compensation related to restricted stock, restricted stock units and stock option awards, net of forfeitures of 34,712 shares   215,842    -*    -     -     3,544    -     3,544 
BALANCE AT September 30, 2025   41,919,141    4    1,718    *    354,641    (290,531)   64,114 

 

*Represents an amount less than $1 thousand
**Represents exercise of pre-funded warrants for cash.

 

The accompanying notes are an integral part of the condensed consolidated financial statements.

 

F-6

 

 

INSPIREMD, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

(Unaudited)

(U.S. dollars in thousands, except share data)

 

   Shares   Amount   Shares   Amount   capital   deficit   equity 
   Common stock   Preferred C
shares
   Additional paid-in   Accumulated   Total 
   Shares   Amount   Shares   Amount   capital   deficit   equity 
                             
BALANCE AT January 1, 2026   43,532,281    4    1,718    *   357,489    (302,292)   55,201 
Net loss                            (37,775)   (37,775)
Issuance of common stock upon exercise of pre-funded warrants   904,029    *    -     -     -     -     -* 
Share-based compensation related to restricted stock, restricted stock units and stock option awards, net of forfeitures of 2,011,348 shares   2,683,128    1    -     -     4,325    -     4,326 
BALANCE AT September 30, 2026   47,119,438    5    1,718    -*    361,814    (340,067)   21,752 

 

*Represents an amount less than $1 thousand

 

The accompanying notes are an integral part of the condensed consolidated financial statements.

 

F-7

 

 

INSPIREMD, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

(Unaudited)

(U.S. dollars in thousands, except share data)

 

   Shares   Amount   Shares   Amount   capital   deficit   equity 
   Common stock   Preferred C
shares
   Additional paid-in   Accumulated   Total 
   Shares   Amount   Shares   Amount   capital   deficit   equity 
                             
BALANCE AT July 1, 2026   46,921,061    5    1,718    

-*

   361,811    (330,305)   31,511 
Net loss                            (9,762)   (9,762)
Issuance of common stock upon exercise of pre-funded warrants   904,029    *    -     -     -     -     -* 
Share-based compensation related to restricted stock, restricted stock units and stock option awards, net of forfeitures of 1,674,911 shares   (705,652)   -*    -     -     3    -     3 
BALANCE AT September 30, 2026   47,119,438    5    1,718    -*    361,814    (340,067)   21,752 

 

*Represents an amount less than $1 thousand

 

The accompanying notes are an integral part of the condensed consolidated financial statements.

 

F-8

 

 

INSPIREMD, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(U.S. dollars in thousands)

 

   2026   2025 
   Nine months ended
September 30
 
   2026   2025 
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net loss  $(37,775)  $(37,025)
Adjustments required to reconcile net loss to net cash used in operating activities:          
Depreciation   475    333 
Gain from sale of property, plant and equipment   -    (15)
Change in fair value of marketable securities, net of interest received   272    (178)
Change in liability for employee rights upon retirement   269    371 
Other financial income   (23)   (113)
Change in operating right of use asset and operating leasing liability   (37)   480 
Share-based compensation expenses   4,326    9,484 
Gain on amounts funded in respect of employee rights upon retirement, net   (48)   (121)
Changes in operating assets and liability items:          
Decrease in prepaid expenses   219    115 
Decrease (increase) in trade receivables   273    (389)
Decrease (increase) in other receivables   (44)   207 
Decrease (increase) in inventory   405    (1,037)
Increase in trade payables   307    499 
Increase (decrease) in other payables   (2,479)   1,631 
Net cash used in operating activities   (33,860)   (25,758)
CASH FLOWS FROM INVESTING ACTIVITIES:          
Purchase of property, plant and equipment   (781)   (1,264)
Proceeds from sale of property, plant and equipment   -    15 
Investments in marketable securities   -    (11,749)
Proceeds from matured marketable securities   45,000    27,648 
Amounts funded in respect of employee rights upon retirement   (62)   (75)
Net cash provided by investing activities   44,157    14,575 
CASH FLOWS FROM FINANCING ACTIVITIES:          
Proceeds from exercise of warrants   -    16,855 
Proceeds from issuance of shares and pre-funded warrants, net of $0 and $3,148 issuance costs, respectively   -    38,714 
Net cash provided by financing activities   -    55,569 
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS   10    101 
INCREASE IN CASH AND CASH EQUIVALENTS   10,307    44,487 
BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF THE PERIOD   8,939    18,916 
BALANCE OF CASH AND CASH EQUIVALENTS AT END OF THE PERIOD  $19,246   $63,403 
SUPPLEMENT NON-CASH INVESTING AND FINANCING ACTIVITIES:          
Acquisition of right-of-use assets by means of lease liabilities
   -    994 
Non-cash purchase of property and equipment   57    101 

 

The accompanying notes are an integral part of the condensed consolidated financial statements.

 

F-9

 

 

INSPIREMD, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 1 - DESCRIPTION OF BUSINESS

 

  a. General
   

 

InspireMD, Inc., a Delaware corporation (the “Company”), together with its subsidiaries in Israel and Germany, is a medical device company specializing in the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions. The Company’s portfolio includes two commercial platforms based on its proprietary CGuard™ carotid stent technology, designed to provide market-leading embolic protection during and after stenting procedures. A stent is an expandable scaffold-like metallic device placed in an artery to widen the lumen and restore blood flow.

     
    The Company’s first platform, the CGuard™ Carotid Embolic Prevention System (“CGuard EPS”), integrates a self-expanding nitinol stent with a MicroNet™ mesh sleeve as a single device for carotid artery revascularization. The Company has received CE Mark recertification for CGuard EPS under the EU Medical Device Regulation (“MDR”). The Company’s CGuard EPS previously held CE Mark approval under the former Medical Device Directive (“MDD”). CGuard EPS is marketed in over 30 countries outside the United States, mainly in Europe, through a network of distributors. In the first quarter of 2026, the Company submitted a premarket approval (“PMA”) to the U.S. Food and Drug Administration (“FDA”) for the CGuard EPS.
     
   

The Company’s second platform, the CGuard™ Prime Carotid Stent System (“CGuard Prime”), uses the same stent and MicroNet mesh with a differentiated deployment mechanism. CGuard Prime for use in carotid artery stenting (“CAS”) procedures (“CGuard Prime 135 cm”) received PMA by the FDA on June 23, 2025. CGuard Prime 135 cm also received MDR CE Mark approval on June 12, 2025. CGuard Prime for use in transcarotid artery revascularization (“TCAR”) procedures (“CGuard Prime 80 cm”) received PMA by the FDA on November 9, 2026, see note 7(d).

 

In May 2026, the Company announced a voluntary recall in the U.S. of CGuard Prime 135 cm, initiated in consultation with the FDA after the Company determined during a controlled launch that the technical success rate of its delivery system did not meet performance expectations. The voluntary action was limited to the CGuard Prime 135 cm delivery system and did not involve the CGuard stent implant. The Company’s assessment did not identify new safety concerns for patients who had previously received a CGuard implant.

     
   

As of September 30, 2026, all affected products were returned and credits were issued to customers. The Company recorded approximately $734,000 as a reduction of revenue related to these returns. In addition, the Company recorded approximately $612,000 of inventory impairment associated with the recall. No additional reduction of revenue or inventory impairment related to the recall was recorded during the three months ended September 30, 2026.

 

F-10

 

 

  b.

Liquidity

 

   

The Company has an accumulated deficit as of September 30, 2026, as well as a history of net losses and negative operating cash flows. The Company expects to continue incurring losses and negative cash flows from operations until the Company expands its commercial revenue to a scale that funds its commercial resources, development activities and support functions. As a result of these expected losses and negative cash flows from operations, along with the Company’s current cash position, the Company does not have sufficient resources to fund operations for at least the next 12 months from the date these condensed consolidated financial statements are issued. Therefore, there is substantial doubt about the Company’s ability to continue as a going concern. These financial statements have been prepared assuming that the Company will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty.

 

On November 16, 2026, the Company closed the November 2026 Offering, as described in Note 15a, resulting in gross proceeds of approximately $37.5 million, before deducting underwriting discounts and commissions and estimated offering expenses.

 

On July 17, 2026, the Company received a notification letter from the Nasdaq Listing Qualifications notifying the Company that it was not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days, or until January 13, 2027, to regain compliance. If the Company does not regain compliance by that date, it may be eligible for an additional 180 calendar day compliance period, subject to satisfying certain continued listing and initial listing requirements. If the Company does not regain compliance within the applicable compliance period, its common stock would be subject to delisting from The Nasdaq Capital Market, which could adversely affect the Company’s ability to raise additional capital.

 

Management’s plans include the continued commercialization of the Company’s products and raising capital through the sale of additional equity securities, debt or capital inflows from potential strategic partnerships and exercises of warrants. There are no assurances, however, that the Company will be successful in obtaining the level of financing needed for its operations. If the Company is unsuccessful in commercializing its products and raising capital, it may need to reduce activities, curtail or cease operations.

     
  c.

Risks Related to the Company’s Operations in Israel 

 

   

On October 7, 2023, Hamas launched a series of attacks on civilian and military targets in Southern Israel and Central Israel, to which the Israel Defense Forces responded. In addition, Iran, Hezbollah and the Houthi movement attacked military and civilian targets in Israel, to which Israel responded, including through increased air and/or ground operations in Lebanon, Syria, Yemen and Iran. On October 9, 2025, Israel, Hamas, the United States and other countries in the region agreed to a framework for a ceasefire in Gaza between Israel and Hamas. On February 28, 2026, the United States and Israel launched joint combat operations in Iran, to which Iran and Hezbollah responded with ballistic missile and drone attacks on Israel, as well as on other countries and U.S. military bases in the region. Although the United States and Iran have announced ceasefire and de-escalation arrangements from time to time, including a memorandum of understanding entered into on June 17, 2026 that contemplates the termination of military operations on multiple fronts, hostilities have resumed and may continue or escalate. A broader regional conflict involving additional state and non-state actors remains a significant risk. The duration and severity of the conflicts in Gaza, northern Israel, Lebanon, Iran and the broader region are unknown at this time, and any renewed or continued clash among Israel, Hamas, Hezbollah, Iran or other countries or militant groups in the region may escalate in the future into a greater regional conflict. Continued military escalation, retaliatory actions, or broader regional involvement may adversely affect economic conditions, disrupt markets, and create uncertainty that could negatively impact the Company’s business, financial condition and results of operations. As of the date of these condensed consolidated financial statements, conflict continues in parts of the region. The Company’s current manufacturing facility, certain of its key personnel and one of its offices are located in Israel. At this time, these activities remain largely unaffected.

 

    During the three and nine months ended September 30, 2026 and 2025, the impact of these conflicts on the Company’s results of operations and financial condition was immaterial, but such impact may increase, which could be material, as a result of the continuation, escalation or expansion of these conflicts.

 

F-11

 

 

NOTE 2 - BASIS OF PRESENTATION

 

The accompanying unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements. In the opinion of the Company, the financial statements reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of its financial position as of September 30, 2026, and its results of operations, changes in equity and cash flows for the three and nine months ended September 30, 2026, and 2025. These unaudited condensed consolidated financial statements and notes thereto are unaudited and should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2025, as found in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 18, 2026. The results of operations for the nine and three months ended September 30, 2026, are not necessarily indicative of results that could be expected for the entire fiscal year.

 

NOTE 3 - RECENTLY ADOPTED AND ISSUED ACCOUNTING PRONOUNCEMENTS

 

Recently issued accounting pronouncement, not yet adopted

 

In November 2024, the FASB issued ASU No. 2024-03 Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40). The ASU improves the disclosures about a public business entity’s expense and provides more detailed information about the types of expenses in commonly presented expense captions. The amendments require that at each interim and annual reporting period an entity will, inter alia, disclose amounts of purchases of inventory, employee compensation, depreciation and amortization included in each relevant expense caption (such as cost of sales, G&A, S&M and research and development) as well as disclosures about selling expenses. The ASU is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating this ASU to determine its impact on the Company’s consolidated financial statements and disclosures.

 

NOTE 4 - FAIR VALUE MEASUREMENTS

 

Fair value is based on the price that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows:

 

Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

 

Level 2: Observable prices that are based on inputs not quoted on active markets but corroborated by market data.

 

Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

 

F-12

 

 

The Company’s financial assets subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows:

 

   Total   Level 1   Level 2   Level 3 
  

As of September 30, 2026

($ in thousands)

 
   Total   Level 1   Level 2   Level 3 
                 
Assets:                    
Cash equivalents-                    
Money market funds  $15,341   $15,341   $-   $- 

 

   Total   Level 1   Level 2   Level 3 
  

As of December 31, 2025

($ in thousands)

 
   Total   Level 1   Level 2   Level 3 
                 
Assets:                    
Cash equivalents-                    
Money market funds  $5,116   $5,116   $-   $- 
                     
Marketable securities-                    
U.S. government bonds  $45,272   $-   $45,272   $- 

 

The Company’s cash equivalents, and marketable securities are classified within Level 1 and Level 2 because it uses quoted market prices or alternative pricing sources and models utilizing market observable inputs to determine their fair value.

 

The cost of marketable securities as of December 31, 2025, is $45,091 thousand.

 

F-13

 

 

NOTE 5 - MARKETABLE SECURITIES

 

As of the end of the quarter, all securities had already matured.

 

The table below sets forth a summary of the changes in the fair value of the Company’s marketable securities for the nine-month period ended September 30, 2026, and 2025:

 

   2026   2025 
  

Nine months ended

September 30,

 
   2026   2025 
   ($ in thousands) 
     
Balance at beginning of the period  $45,272   $15,721 
Additions   -    11,749 
Maturity   (45,000)   (27,648)
Interest received   (860)   (109)
Changes in fair value during the period   588    287 
Balance at end of the period   -    - 

 

NOTE 6 - RESTRUCTURING AND OTHER CHARGES

 

During the third quarter of 2026, the Company approved and completed a workforce reduction and efficiency plan designed to align its operating structure and cost base with its strategic priorities. The plan included employee terminations in the United States and certain EMEA countries, together with related separation, benefit-continuation, outplacement and directly attributable advisory activities.

 

For the three and nine months ended September 30, 2026, the Company recognized restructuring and related charges of $1,074 thousand in the condensed consolidated statements of operations. Employee termination and separation benefits consisted of $614 thousand of one-time involuntary termination benefits accounted for under ASC 420 and $391 thousand of statutory and contractual termination benefits accounted for under ASC 712. The remaining $69 thousand consisted of legal fees associated with the restructuring. The Company does not currently expect additional material costs under the plan.

 

F-14

 

 

The following table summarizes the charges recognized under the plan (in thousands):

 

 

  

Three months

ended

September 30, 2026

  

Nine months

ended

September 30, 2026

 
         
One-time involuntary termination benefits (ASC 420)  $614   $614 
Statutory and contractual termination benefits (ASC 712)  $391   $391 
Total employee termination and separation benefits  $1,005   $1,005 
           
Legal and advisory fees and other restructuring costs  $69   $69 
Total restructuring and related charges  $1,074   $1,074 

 

The following table summarizes activity in the restructuring-related liability (in thousands):

 

Liability activity 

Nine months
ended

September 30, 2026

 
Balance on January 1, 2026  $— 
One-time involuntary termination charges (ASC 420)   614 
Statutory and contractual termination charges (ASC 712)   391 
Total employee termination and separation charges   1,005 
Cash payments   (561)
Balance on September 30, 2026  $444 

 

The remaining liability is included in accounts payable and accruals—other and is expected to be settled within six months. Legal and advisory fees and outplacement costs are expensed as incurred and therefore are not included in the liability rollforward.

 

NOTE 7 - EQUITY

 

  a. Authorized Capital Stock
     
    As of September 30, 2026, the Company had 255,000,000 authorized shares of capital stock, par value $0.0001 per share, of which 250,000,000 are shares of common stock and 5,000,000 are shares of “blank check” preferred stock.
     
  b. Preferred Stock
     
   

As of September 30, 2026, there were 1,718 shares of Series C preferred stock outstanding, convertible into an aggregate of 14,328 shares of the Company’s common stock, with a total stated value of $10,997.

 

Pursuant to the full ratchet anti-dilution adjustment provisions in the certificate of designation for the Company’s Series C preferred stock, following the Warrant Amendments described in Note 7d, the conversion price of the outstanding shares of Series C preferred stock was reduced from $1.3827 to $0.7674 per share, effective as of September 21, 2026, and the number of shares of common stock issuable upon conversion of the Series C preferred stock increased by 6,376 additional shares, to an aggregate of 14,328 shares.

 

  c. Pre-Funded Warrants
     
    As of September 30, 2026, there were 42,188,078 outstanding pre-funded warrants.

 

F-15

 

 

  d. Warrants
     
    On September 21, 2026, the Company entered into amendments (the “Warrant Amendments”) with certain holders of its outstanding Series J and Series K warrants (collectively, the “Existing Warrants”). Pursuant to the Warrant Amendments, the Company amended Series J warrants covering 4,771,980 shares, representing 50% of the shares underlying the participating holders’ Series J warrants, and Series K warrants covering 9,543,947 shares, representing all of the shares underlying the participating holders’ Series K warrants. The Warrant Amendments reduced the exercise price of the amended warrants from $1.3827 per share to $0.7674 per share (less $0.0001 for holders that elect to receive pre-funded warrants upon exercise) and revised their expiration date to the earlier of May 15, 2028 and 20 trading days following the Company’s announcement of receipt of FDA approval for CGuard Prime 80 cm. The exercise price and expiration date of the remaining 50% of the participating holders’ Series J warrants remained unchanged. All terms and conditions of Series J and Series K warrants held by holders that did not enter into the Warrant Amendments also remained unchanged and in full force and effect. All other terms and conditions of the Existing Warrants remained unchanged and in full force and effect.
     
   

The Company accounted for the Warrant Amendments as modifications of equity-classified warrants and measured the modification effect as the excess of fair value immediately after modification over fair value immediately before modification. The resulting incremental fair value of $684 thousand was recognized as a deemed dividend for the three and nine months ended September 30, 2026. The deemed dividend did not affect net loss or total equity, but increased loss available to common stockholders and basic and diluted net loss per share. In addition, as a result of the Warrant Amendments, the conversion price of the Series C preferred stock was adjusted pursuant to its anti-dilution provisions. See Note 7b.

 

As of September 30, 2026, the Company has outstanding warrants to purchase an aggregate of 25,828,164 shares of common stock as follows:

 

Classification  Series J   Series K  

Total warrants

amount

   Exercise
price
   Expiration
date
 
Amended   4,771,980    9,543,947    14,315,927   $0.7674    * 
Unamended   8,142,106    3,370,131    11,512,237   $1.3827    * 
Total   12,914,086    12,914,078    25,828,164    —    — 

 

*Amended Series J warrants and Amended Series K warrants: expire on the earlier of May 15, 2028 and 20 trading days after the Company announces FDA approval for CGuard Prime 80 cm.

 

Unamended Series J warrants: expire on the earlier of May 15, 2028 and 20 trading days following the Company’s announcement of receipt of FDA approval for SwitchGuard and CGuard Prime 80 cm.

 

Unamended Series K warrants: expire on the earlier of May 15, 2028 and 20 trading days following the end of the fourth fiscal quarter after the fiscal quarter in which the first commercial sales of CGuard Prime 135 cm in the U.S. began. Subsequent to that date, the unamended Series K warrants expired unexercised on October 28, 2026.

 

On November 12, 2026, the Company announced FDA approval for CGuard Prime 80 cm. Accordingly, the amended Series J warrants and amended Series K warrants will expire on December 11, 2026, which is 20 trading days after the announcement, unless exercised prior to that date.

 

During the nine months ended September 30, 2026, a total of 1,092,344 Series G warrants expired unexercised.

 

  e. Share-Based Compensation
     
    During the nine months ended September 30, 2026, the Company granted 4,694,476 restricted shares of common stock to employees and directors. Employee awards generally vest over three years, typically in annual installments, although certain employee awards vest over one year or have individualized vesting schedules, subject to continued service. Director awards vest over one year, subject to continued service.
     
    The fair value of the above restricted shares was approximately $6.6 million.
     
   

During the nine months ended September 30, 2026, the Company granted 1,114,792 restricted stock units convertible into shares of the Company’s common stock to the Company’s chief executive officer. The restricted stock units are subject to a three-year vesting period, with one-third of such awards vesting each year, subject to continued service.

     
    The fair value of the above restricted stock units was approximately $1.8 million

 

F-16

 

 

NOTE 8 - RELATED PARTY TRANSACTIONS

 

During the three and nine months ended September 30, 2025, administrative services provided by a member of the chief executive officer’s immediate family in connection with the Company’s expansion to the U.S. amounted to $8 and $56 thousand, respectively. The engagement with the related party was terminated in July 2025.

 

NOTE 9 - NET LOSS PER SHARE

 

Basic and diluted net loss per share is computed by dividing the net loss for the period by the weighted average number of shares of common stock, pre-funded warrants and fully vested restricted stock units outstanding during the period. The calculation of diluted net loss per share excludes the potentially dilutive effects of share options, warrants, unvested restricted stock, unvested restricted stock units and Series C preferred stock because their effects are anti-dilutive.

 

For the purpose of calculating basic net loss per share, the additional shares of common stock that are issuable upon exercise of the pre-funded warrants have been included since the shares are issuable for a negligible consideration, as determined by the Company according to ASC 260-10-45-13, and have no vesting or other contingencies associated with them.

 

The total numbers of shares of common stock underlying outstanding options, warrants, unvested restricted stock, unvested restricted stock units and Series C preferred stock excluded from the calculation of diluted net loss per share were 36,615,752 and 37,695,155 for the nine- and three-month periods ended September 30, 2026 and 2025, respectively. These amounts include 5,339,275 and 5,385,272 shares of unvested restricted stock included in the number of issued and outstanding shares as of September 30, 2026 and 2025, respectively.

 

For the three and nine months ended September 30, 2026, and 2025, the weighted average number of common stock used in computing net loss per share - basic and diluted was as follows:

 

   2026   2025   2026   2025 
  

Three months ended
September 30,

  

Nine months ended
September 30,

 
   2026   2025   2026   2025 
Weighted average number of common stock   40,876,590    33,741,698    40,029,176    27,560,829 
Weighted average vested restricted stock units   1,844,034    1,121,678    1,646,561    931,022 
Weighted average pre-funded warrants   42,895,579    38,603,125    43,025,878    29,753,517 
Total weighted average number of common shares used in computing net loss per share (basic and diluted)   85,616,203    73,466,501    84,701,615    58,245,368 

 

During the three and nine months ended September 30, 2026, the Company recognized a deemed dividend of approximately $684 thousand in connection with the warrant amendments described in Note 7(d). The deemed dividend increased loss available to common stockholders and basic and diluted net loss per share for those periods.

 

F-17

 

 

The following table presents the reconciliation of net loss to net loss available to common stockholders after giving effect to the deemed dividend:

 

(U.S. dollars in thousands) 

Three months

ended

September 30, 2026

  

Nine months

ended

September 30, 2026

 
Net loss  $(9,762)  $(37,775)
Deemed dividend   (684)   (684)
Net loss available to common stockholders  $(10,446)  $(38,459)

 

NOTE 10 - FINANCIAL INSTRUMENTS

 

a.Fair value of financial instruments
   
  As of September 30, 2026, and December 31, 2025, the carrying amounts of accounts payable, accounts receivable and other receivables approximate their fair values due to the short-term maturities of these instruments.
   
  The carrying amount of the long-term deposit approximates its fair value since it is measured at its present value applying prevailing interest rates.
   
b.As of September 30, 2026, and December 31, 2025, the allowance for expected credit loss was immaterial.

 

NOTE 11 - INVENTORY:

 

   September 30,   December 31, 
   2026   2025 
   ($ in thousands) 
Finished goods  $97   $352 
Work in process   1,151    930 
Raw materials and supplies   1,743    2,114 
Total inventory   $2,991   $3,396 

 

*The Company recorded approximately $612 thousand of inventory impairment in connection with the voluntary recall during the nine months ended September 30, 2026.

 

NOTE 12 - ACCOUNTS PAYABLE AND ACCRUALS – OTHER

 

   September 30,   December 31, 
   2026   2025 
   ($ in thousands) 
Employees and employee institutions  $2,815   $4,925 
Accrued vacation and recreation pay   570    430 
Accrued expenses   875    1,545 
Clinical trial accrual   996    1,155 
Current Operating lease liabilities   1,038    1,066 
Customer credit balances*   417    2 
Other   296    334 
Accounts Payable and Accruals - Other  $7,007   $9,457 

 

*U.S. revenues for the nine months ended September 30, 2026 include approximately $734 thousand of credits issued in connection with the voluntary recall described in Note 1(a).

 

NOTE 13 - DISAGGREGATED REVENUE AND ENTITY-WIDE DISCLOSURES

 

Revenues are attributed to geographic areas based on the location of the customers. The following is a summary of revenues:

 

   2026   2025   2026   2025 
   Three months
ended
September 30,
   Nine months
ended
September 30,
 
   2026   2025   2026   2025 
   ($ in thousands) 
                 
Germany  $202   $380   $722   $982 
Italy   316    293    973    878 
Poland   352    211    915    686 
USA**   32    497    859    551 
Other*   1,340    1,142    3,942    2,733 
Revenues  $2,242   $2,523   $7,411   $5,830 

 

*Revenues from all other countries, individually, did not exceed 10% of total revenues for the three- and nine-month periods ended September 30, 2026 and 2025.
**U.S. revenues for the nine months ended September 30, 2026 include approximately $734 thousand of credits issued in connection with the voluntary recall (see Note 1(a)).

 

F-18

 

 

By principal customers (part of revenues):

 

   2026   2025   2026   2025 
   Three months ended
September 30,
   Nine months ended
September 30,
 
   2026   2025   2026   2025 
Customer A   9%   15%   10%   17%
Customer B   13%   4%   10%   9%

 

NOTE 14 - SEGMENT INFORMATION

 

The Company has one operating and reporting segment that develops, manufactures and markets products for the treatment of carotid artery disease and other vascular disease, including the Company’s proprietary CGuard™ stent platform. The Company’s Chief Operating Decision Maker (“CODM”), who is the chief executive officer, evaluates the Company’s performance based on its internal reporting which is consistent with the presentation in the Company’s consolidated financial statements. Accordingly, our CODM uses consolidated net loss to measure segment profit or loss, allocate resources, and assess performance.

 

The CODM examines, within each operational function, the employee salaries including the bonus and share based compensation. In addition, the CODM examines the clinical trials expenses within the research and development operations.

 

   2026   2025   2026   2025 
   Three months ended
September 30,
   Nine months ended
September 30,
 
   2026   2025   2026   2025 
Revenues   2,242    2,523    7,411    5,830 
                     
Cost of Revenues:                    
Material and Labor   1,725    1,391    5,047    3,554 
Other cost of revenues   277    268    1,126    807 
Inventory write-off   -    -    1,085    - 
Total Cost of Revenues   2,002    1,659    7,258    4,361 
                     
Research and development (R&D)                    
Payroll and Benefits   1,178    1,089    4,059    3,063 
Share based compensation   (204)   576    406    1,889 
Clinical trials   1,224    1,105    3,663    3,401 
Other R&D   1,075    865    4,203    3,175 
Total Research and development   3,273    3,635    12,331    11,528 
                     
Selling and marketing (S&M)                    
Payroll and Benefits   2,618    2,975    10,411    7,732 
Share based compensation   (649)   567    475    1,379 
Other S&M   425    850    1,909    2,203 
Total Selling and marketing   2,394    4,392    12,795    11,314 
                     
General and administrative (G&A)                    
Payroll and Benefits   1,185    1,707    4,148    5,015 
Share based compensation   801    2,351    3,267    6,051 
Other G&A   1,466    1,830    4,914    5,091 
Total General and administrative   3,452    5,888    12,329    16,157 
                     
Total Restructuring   1,074    -    1,074    - 
                     
Financial Income (expenses), net;   191    343    601    505 
Segment net loss   (9,762)   (12,708)   (37,775)   (37,025)

 

NOTE 15 - SUBSEQUENT EVENTS:

 

a.Subsequent to September 30, 2026, on November 13, 2026, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Lake Street Capital Markets, LLC, as representative (the “Representative”) of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale in an underwritten public offering (the “November 2026 Offering”) of (i) 7,342,308 shares of common stock, and pre-funded warrants to purchase up to 50,350,000 shares of common stock (the “November 2026 Pre-Funded Warrants”), and (ii) accompanying Series L warrants to purchase up to 43,269,231 shares of common stock (or, at the election of the holder, November 2026 Pre-Funded Warrants to purchase up to an equal number of shares of common stock in lieu thereof) (the “Series L Warrants” and, together with the November 2026 Pre-Funded Warrants, the “November 2026 Warrants”), representing 75% of the aggregate number of shares of common stock and November 2026 Pre-Funded Warrants sold in the November 2026 Offering. Each share of common stock is being sold together with an accompanying Series L Warrant at a combined public offering price of $0.65, and each November 2026 Pre-Funded Warrant is being sold together with an accompanying Series L Warrant at a combined public offering price of $0.6499, which equals the combined public offering price per share of common stock and accompanying Series L Warrant, minus $0.0001.

 

The November 2026 Offering closed on November 16, 2026. The gross proceeds from the November 2026 Offering were approximately $37.5 million, and the Company estimates that the gross proceeds from the November 2026 Offering will be approximately $43.1 million if the Representative exercises its option to purchase additional securities in full (as further described below), in each case, prior to deducting underwriting discounts and commissions and estimated offering expenses payable by the Company, and excluding the proceeds, if any, from the exercise of the Warrants.

 

Each November 2026 Pre-Funded Warrant has an exercise price of $0.0001 per share of common stock, is immediately exercisable upon issuance and may be exercised at any time until exercised in full. Each Series L Warrant has an exercise price of $0.65 per share of common stock, is immediately exercisable upon issuance, will expire one year from the date of issuance and may be exercised, at the holder’s election, for pre-funded warrants in lieu of shares of common stock. A holder may not exercise any portion of its November 2026 Warrants to the extent that the holder, together with its affiliates and attribution parties, would beneficially own more than 4.99% (or, at the election of the holder, 9.99%) of the outstanding common stock immediately after exercise.

 

The Company also granted the Representative a 30-day option to purchase up to 8,653,846 additional shares of common stock and/or pre-funded warrants to purchase up to 8,653,846 shares of common stock and/or Series L Warrants to purchase up to 6,490,384 shares of common stock (or pre-funded warrants in lieu thereof) (or any combination thereof) at the applicable public offering price minus underwriting discounts and commissions, representing 15% of the total number of shares of common stock, November 2026 Pre-Funded Warrants and Series L Warrants sold in the November 2026 Offering, solely to cover over-allotment, if any. As of the date hereof, the Representative has not exercised this option.

 

b.Pursuant to the full ratchet anti-dilution adjustment provisions in the certificate of designation for the Company’s Series C preferred stock, following the November 2026 Offering described in Note 15a, the conversion price of the outstanding shares of Series C preferred stock was reduced from $0.7674 to $0.6499 per share, effective as of November 13, 2026, and the number of shares of common stock issuable upon conversion of the Series C preferred stock increased by 2,590 additional shares, to an aggregate of 16,918 shares.

 

F-19

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the accompanying condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q.

 

Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q to the “Company,” “InspireMD,” “we,” “our” and “us” refer to InspireMD, Inc., a Delaware corporation, and its subsidiaries.

 

Forward-Looking Statements

 

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which include information relating to future events, future financial performance, strategies, expectations, competitive environment and regulation, including revenue growth. Words such as “may,” “will,” “should,” “could,” “would,” “predicts,” “potential,” “continue,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” and similar expressions, as well as statements in future tense, identify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Forward-looking statements are based on information we have when those statements are made or our management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause such differences include, but are not limited to:

 

  ● our history of recurring losses and negative cash flows from operating activities, significant future commitments and the uncertainty regarding the adequacy of our liquidity to pursue our complete business objectives, and substantial doubt regarding our ability to continue as a going concern;
     
  ● our need to raise additional capital to meet our business requirements in the future and such capital raising may be costly or difficult to obtain and could dilute our stockholders’ ownership interests;
     
  ● the clinical development, commercialization and market acceptance of our products;
     
  ● whether the clinical trial results for our products will be predictive of real-world results;
     
  ● an inability to secure and maintain regulatory approvals for the sale of our products;
     
  ● any impact of a product recall, including the voluntary recall in the U.S. of the CGuard Prime 135cm Carotid Stent System, or any future product recall, on our business, results of operations and financial condition;
     
  ● negative clinical trial results or lengthy product delays in key markets;
     
  ● our ability to maintain compliance with the Nasdaq listing standards;
     
  ● our ability to generate significant revenues from our products;
     
  ● estimates of our expenses, future revenues, capital requirements and our needs for and ability to access sufficient additional financing, including any unexpected costs or delays in resuming U.S. commercialization of CGuard Prime following the voluntary recall or in the commercial launch of our other products;
     
  ● our dependence on a single manufacturing facility and our ability to comply with stringent manufacturing quality standards and to increase production as necessary;
     
  ● the risk that the data collected from our current and planned clinical trials may not be sufficient to demonstrate that our technology is an attractive alternative to other procedures and products;

 

  ● intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do;
     
  ● entry of new competitors and products and potential technological obsolescence of our products;
     
  ● inability to carry out research, development and commercialization plans;
     
  ● loss of a key customer or supplier;
     
  ● technical problems with our research and products and potential product liability claims;
     
  ● product malfunctions;
     
  ● price increases for supplies and components;
     
  ● whether access to our products is achieved in a commercially viable manner and whether our products receive adequate reimbursement by governmental and other third-party payers;
     
  ● our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful;
     
  ● adverse federal, state and local government regulation, in the United States, Europe or Israel and other foreign jurisdictions;
     
  ● the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction;

 

2
 

 

  ● security, political and economic instability in the Middle East that could harm our business, including due to the current security situation in Israel;
     
  ● current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk; and
     
  ● changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements and the impact of such policies on us, our customers and suppliers, and the global economic environment.

 

The foregoing does not represent an exhaustive list of matters that may be covered by the forward-looking statements contained herein or risk factors that we face that may cause our actual results to differ from those anticipated in our forward-looking statements. For a discussion of these and other risks that relate to our business and investing in our common stock, you should carefully review the risks and uncertainties described under “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (the “SEC”) on March 18, 2026, in Part II, Item 1A of this Quarterly Report on Form 10-Q and in our subsequent reports filed with the SEC. The forward-looking statements contained in this Quarterly Report on Form 10-Q are expressly qualified in their entirety by this cautionary statement. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

 

Overview

 

We are a medical device company specializing in the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions. Our portfolio includes two commercial platforms based on our proprietary CGuard carotid stent technology, designed to provide market-leading embolic protection during and after stenting procedures. A stent is an expandable scaffold-like metallic device placed in an artery to widen the lumen and restore blood flow.

 

Our first platform, the CGuard Carotid Embolic Prevention System (“CGuard EPS”), integrates a self-expanding nitinol stent with a MicroNet mesh sleeve as a single device for carotid artery revascularization. In January 2024, we received CE Mark recertification for CGuard EPS under the EU Medical Device Regulation (“MDR”). Our CGuard EPS previously held CE Mark approval under the former Medical Device Directive (“MDD”). CGuard EPS is marketed in over 30 countries outside the United States through a network of distributors. In the first quarter of 2026, we submitted a premarket approval application to the U.S. Food and Drug Administration (“FDA”) for CGuard EPS with potential for FDA approval in the fourth quarter of 2026.

 

Our second platform, the CGuard Prime Carotid Stent System (“CGuard Prime”), uses the same stent and MicroNet mesh as CGuard EPS with a differentiated deployment mechanism. We have two distinct products within the CGuard Prime platform for use in different procedures to implant the stent. The first product was designed for use in carotid artery stenting (“CAS”) procedures and utilizes a 135 cm catheter as part of the delivery system (“CGuard Prime 135 cm”). The second product was designed for use during transcarotid artery revascularization (“TCAR”) procedures and utilizes a shorter 80 cm catheter in its delivery system (“CGuard Prime 80 cm”).

 

CGuard Prime 135 cm received premarket approval (“PMA”) from the FDA on June 23, 2025 and MDR CE Mark approval on June 12, 2025 for use in CAS procedures. In May 2026, we announced a voluntary recall in the U.S. of CGuard Prime, undertaken in consultation with the FDA after a controlled launch demonstrated that the technical success of its delivery system did not meet performance expectations. The voluntary action pertained specifically to the delivery system and not to the CGuard Prime stent implant. For additional information, see “FDA Matters” below.

 

In October 2024, the FDA approved our investigational device exemption (“IDE”) application to initiate the CGUARDIANS II pivotal study of the CGuard Prime TransCarotid Stent System during transcarotid artery revascularization (“TCAR”) procedures. In the first quarter of 2026, we completed enrollment in the CGUARDIANS II pivotal study, and in June 2026, we announced summary 30-day outcome data from the study, which showed acute device success of 100% with no major adverse events.

 

3
 

 

CGuard Prime 80 cm received premarket approval (“PMA”) from the FDA on November 9, 2026 for use in TCAR procedures. We have commercial inventory of CGuard Prime 80 cm prepared for commercial launch and expect to commence sales promptly in the fourth quarter of 2026.

 

In May 2026, we announced that the FDA had approved our IDE application to initiate the CGUARDIANS III pivotal trial, which evaluates our proprietary SwitchGuard neuroprotection system (“SwitchGuard NPS”) paired with the CGuard Prime TransCarotid Stent System to enable flow-reversal neuroprotection during TCAR, and in June 2026, we announced enrollment of the first patient.

 

In October 2023, the Centers for Medicare & Medicaid Services (“CMS”) issued its final National Coverage Determination (“NCD”), expanding coverage for both CAS and TCAR procedures to include both asymptomatic and standard surgical risk patients, which we believe significantly expands and supports the future growth of the U.S. addressable market for CAS.

 

In November 2025, the results of the CREST-2 study were released, which showed that CAS combined with medical therapy demonstrated a significantly lower stroke risk as compared to intensive medical management alone in patients with severe asymptomatic carotid stenosis. CREST-2 was an independent study sponsored by the National Institutes of Health (“NIH”) with a set of two parallel, observer-blinded clinical trials across 155 centers globally. CREST-2 showed that, among patients with high-grade carotid stenosis without recent neurological symptoms, the addition of stenting led to significantly better outcomes than intensive medical management alone, as measured by a decreased risk of the composite of perioperative stroke or death or ipsilateral stroke within four years. In a separate arm of the same trial, carotid endarterectomy (“CEA”) did not achieve a significant benefit for these patients as compared to intensive medical management alone.

 

We continue to invest in new product generations and potential new clinical indications for the CGuard platform with a strategy of focusing on advancing a “stent-first” approach to carotid revascularization. As part of this strategy, we are evaluating the CGuard Prime TransCarotid Stent System in TCAR-based clinical programs, including the CGUARDIANS II pivotal trial, which studied the use of the CGuard Prime TransCarotid Stent System in conjunction with an established neuroprotection device, and the CGUARDIANS III pivotal trial, which evaluates our proprietary SwitchGuard neuroprotection system paired with the CGuard Prime TransCarotid Stent System to enable flow-reversal neuroprotection during TCAR. In parallel, we are pursuing new clinical applications outside TCAR, including the treatment of acute ischemic stroke with tandem lesions. In this acute-stroke setting, the flexible, low-metal-burden design and MicroNet mesh of the CGuard Prime Carotid Stent may offer advantages where traditional embolic-protection devices cannot be used. We initially partnered with Jacobs Institute to fund an early feasibility study in this area but discontinued our support as part of an initiative to reduce our operating expenses. For additional information, see “Workforce Reduction Initiative” below.

 

We consider our current addressable market for our CGuard EPS, CGuard Prime, and SwitchGuard NPS to be both symptomatic and asymptomatic individuals with diagnosed high-grade carotid artery stenosis for whom intervention is preferable to medical (drug) therapy. This group includes not only patients eligible for either CAS or TCAR procedures, but also individuals who are candidates for CEA, as all three approaches can be options to treat these patients. Assuming full penetration of the intervention caseload, we estimate that the addressable market for CGuard EPS, CGuard Prime, and SwitchGuard NPS is approximately $1.3 billion (source: Health Research International Personal Medical Systems, Inc. September 13, 2021 Results of Update Report on Global Carotid Stenting Procedures and Markets by Major Geography and Addressable Markets and internal estimates). According to this same report and internal estimates, assuming full penetration of treatment for all individuals diagnosed with high-grade carotid artery stenosis, we estimate the total available market for CGuard EPS, CGuard Prime, and SwitchGuard NPS to be approximately $9.3 billion, which may grow over time if expanded treatment options such as our products lead to increased patient screening for carotid artery disease.

 

4
 

 

FDA Matters

 

In May 2026, we announced a voluntary recall in the U.S. of the CGuard Prime 135 cm product, initiated in consultation with the FDA. The Company acted after determining during a controlled launch that the technical success rate of the CGuard Prime 135 cm delivery system had not met performance expectations. The voluntary action was limited to the CGuard Prime 135 cm delivery system and did not involve the CGuard stent implant. Our assessment did not identify new safety concerns for patients who had previously received a CGuard implant. We believe we have identified the root cause of the performance-related issues that caused the recall and are implementing design modifications intended to address them. We are currently performing verification and validation testing of these modifications in support of a PMA supplement to the FDA which we expect to submit in the fourth quarter of 2026. We cannot provide any assurance that the FDA will be satisfied with the corrective actions we are implementing in connection with the voluntary recall, or as to the timing of the resolution of such issues. Until these issues are resolved to the FDA’s satisfaction, we may be unable to resume commercialization of CGuard Prime 135 cm in the United States. If the FDA determines that our corrective actions are inadequate or requires additional remediation, testing, validation or regulatory submissions, such requirements could increase costs, delay or prevent FDA acceptance or approval of our proposed PMA supplement, extend the duration of the voluntary recall, delay our ability to reintroduce CGuard Prime 135 cm to the U.S. market or otherwise adversely affect our future commercialization plans, which could have a material adverse effect on our business, financial condition and results of operations. As of September 30, 2026, all affected products were returned, and credits were issued to customers. In the quarter ended June 30, 2026, we recorded approximately $734,000 as a reduction of revenue related to these returns and approximately $612,000 of inventory impairment associated with the recall. No additional revenue reductions or inventory impairment charges related to the recall were recorded during the quarter ended September 30, 2026.

 

Workforce Reduction Action

 

During the quarter ended September 30, 2026, we completed a workforce reduction (the “Q3’26 Workforce Reduction”) as part of a broader initiative to reduce our operating expenses, improve operational efficiency and better align our resources with our strategic priorities. The Q3’26 Workforce Reduction reduced the number of positions in the organization by approximately 20%. We incurred aggregate restructuring charges of approximately $1.1 million, consisting primarily of employee severance and related employee termination costs and recorded a related liability of approximately $444 thousand in the accompanying consolidated financial statements as of September 30, 2026. We expect these actions to better align our resources with key product development, regulatory, clinical and commercialization priorities while reducing our overall operating expense base.

 

Critical Accounting Policies

 

A critical accounting policy is one that is both important to the portrayal of our financial condition and results of operations and requires management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Our critical accounting policies are more fully described in both (i) “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” and (ii) Note 2 of the Notes to the Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2025. There have not been any material changes to such critical accounting policies since December 31, 2025.

 

The currency of the primary economic environment in which our operations are conducted is the U.S. dollar (“$” or “dollar”).

 

Results of Operations

 

Three months ended September 30, 2026, compared to the three months ended September 30, 2025

 

Revenues. For the three months ended September 30, 2026, revenue was $2,242,000, a decrease of $281,000, or 11.1%, compared to $2,523,000 during the three months ended September 30, 2025. The decrease was primarily attributable to the voluntary recall of CGuard Prime 135 cm in the U.S. in May 2026, which was partially offset by revenues generated from continued growth in sales of CGuard EPS through distributors in international markets.

 

With respect to geographical regions, U.S. revenue was $32,000 for the three months ended September 30, 2026, which was derived from clinical trial activities, compared to $497,000 for the three months ended September 30, 2025. The decrease of $465,000 in U.S. revenue was primarily due to the voluntary recall of CGuard Prime 135 cm. This decrease was partially offset by growth of approximately 9% in international markets, with international revenue increasing to $2,210,000 for the three months ended September 30, 2026, compared to $2,026,000 for the three months ended September 30, 2025, including increases of $125,000 in Asia and $59,000 in all other regions, reflecting continued growth in demand in these markets.

 

5
 

 

Gross Profit. For the three months ended September 30, 2026, gross profit (revenue less cost of revenues) was $240,000 compared to $864,000 for the three months ended September 30, 2025, a decrease of $624,000. The decrease in gross profit was primarily attributable to adverse mix of revenue from the near absence of direct sales in the U.S. following the voluntary recall of CGuard Prime in May 2026, with U.S. revenue declining to $32,000 from $497,000 in the prior-year period. Revenue from direct sales in the U.S. carry higher unit profit due to a higher average selling price compared to sales to international distributors. In addition, we also experienced an adverse mix of sales within the international revenue, with a greater percentage of sales taking place to countries with lower average selling prices as compared to the prior year’s quarter.

 

Gross margin represents our gross profit as a percentage of revenue. Gross margin was 10.7% for the three months ended September 30, 2026, a decrease of 23.5 percentage points compared to gross margin of 34.2% for the three months ended September 30, 2025, primarily due to the factors discussed above.

 

Research and Development Expenses. For the three months ended September 30, 2026, research and development expenses were $3,273,000, a decrease of $362,000, or 10.0%, compared to $3,635,000 during the three months ended September 30, 2025. The decrease was primarily attributable to lower share-based compensation including the reversal of $443,000 of share-based compensation expense associated with forfeited equity awards following the Q3’26 Workforce Reduction and reduced spending on the TCAR and CGUARDIANS programs, partially offset by increased spending on the CGUARDIANS III clinical trial and clinical, regulatory and quality consulting support.

 

Selling and Marketing Expenses. For the three months ended September 30, 2026, selling and marketing expenses were $2,394,000, a decrease of $1,998,000, or 45.5%, compared to $4,392,000 during the three months ended September 30, 2025. This decrease resulted primarily from lower compensation and other personnel-related expenses following the implementation of our Q3’26 Workforce Reduction during the third quarter of 2026, including a decrease in share-based compensation expense due primarily to the reversal of $1,100,000 of expense associated with forfeited equity awards following the workforce reduction.

 

General and Administrative Expenses. For the three months ended September 30, 2026, general and administrative expenses were $3,452,000, a decrease of $2,436,000, or 41.4%, compared to $5,888,000 during the three months ended September 30, 2025. The decrease was primarily driven by lower compensation and personnel-related expenses, including the reversal of $280,000 of share-based compensation expense associated with forfeited equity awards following the Q3’26 Workforce Reduction and the inclusion in the prior-year period of severance and share-based compensation expenses of $220,000 and $721,000, respectively, associated with the departure of an executive.

 

Restructuring Expenses. For the three months ended September 30, 2026, restructuring expenses were $1,074,000 compared with no restructuring expenses in the three months ended September 30, 2025. The expenses primarily consisted of employee severance and related termination benefits associated with the workforce reduction initiative. See Note 6 to the condensed consolidated financial statements.

 

Financial Income. For the three months ended September 30, 2026, financial income was $191,000 compared to financial income of $343,000 during the three months ended September 30, 2025, representing a decrease of $152,000, or 44.3%. The decrease in financial income resulted primarily from lower income from investments in marketable securities and money market funds, partially offset by higher financial income related to changes in exchange rates.

 

Tax Expenses. We did not incur any tax expenses during the three months ended September 30, 2026 and September 30, 2025.

 

Net Loss. For the three months ended September 30, 2026, our net loss was $9,762,000, a decrease of $2,946,000, or 23.2%, compared to $12,708,000 during the three months ended September 30, 2025. The decrease in net loss resulted primarily from a decrease in total operating expenses of $3,722,000, partially offset by a decrease in gross profit of $624,000 and a decrease in financial income of $152,000 compared to the prior-year period.

 

Nine months ended September 30, 2026, compared to the nine months ended September 30, 2025

 

Revenues. For the nine months ended September 30, 2026, revenue was $7,411,000, an increase of $1,581,000, or 27.1%, compared to $5,830,000 during the nine months ended September 30, 2025. The increase was driven mainly by continued growth in sales of CGuard EPS through distributors in international markets and direct sales of CGuard Prime 135 cm in the U.S. prior to the voluntary recall. The increase was partially offset by $734,000 of credits issued in connection with the voluntary recall of CGuard Prime 135 cm in the U.S. during the nine months ended September 30, 2026.

 

6
 

 

With respect to geographical regions, U.S. revenue was $859,000 for the nine months ended September 30, 2026, compared to $551,000 for the nine months ended September 30, 2025. The increase of approximately $308,000 was driven by commercial sales of CGuard Prime 135 cm, partially offset by credits issued in connection with the voluntary recall of CGuard Prime 135 cm in May 2026. International revenue was $6,552,000 for the nine months ended September 30, 2026, compared to $5,279,000 for the nine months ended September 30, 2025. Revenue from international markets grew by $1,273,000, or 24.1%, including increases of $638,000 in Europe, $308,000 in Latin America, $215,000 in Asia, and $110,000 in all other regions. The international sales performance reflects continued growth in demand in these markets.

 

Gross Profit. For the nine months ended September 30, 2026, gross profit (revenue less cost of revenues) was $153,000 compared to gross profit of $1,469,000 for the nine months ended September 30, 2025. The decrease in gross profit was primarily attributable to the voluntary recall of CGuard Prime 135 cm in the U.S., including $734,000 of net credits issued to customers, which reduced revenue, as well as inventory impairment and inventory obsolescence charges totaling $1,085,000 related to the CGuard Prime 135 cm delivery system, which increased cost of revenues. These impacts were partially offset by the year-over-year increase in revenue.

 

Gross margin represents our gross profit as a percentage of revenue. Gross margin was 2.1% for the nine months ended September 30, 2026, a decrease of 23.1 percentage points compared to gross margin of 25.2% for the nine months ended September 30, 2025, primarily due to the factors discussed above.

 

Research and Development Expenses. For the nine months ended September 30, 2026, research and development expenses were $12,331,000, an increase of $803,000, or 7.0%, compared to $11,528,000 during the nine months ended September 30, 2025.

 

The increase was primarily driven by higher clinical trial expenses related to the initiation of the CGUARDIANS III pivotal trial and higher payroll expenses in connection with our expansion in the United States. These increases were partially offset by lower share-based compensation expense, including the reversal of $443,000 of share-based compensation expense associated with forfeited equity awards following the Q3’26 Workforce Reduction and lower clinical trial expenses following the completion of the CGUARDIANS I and CGUARDIANS II pivotal trials.

 

Selling and Marketing Expenses. For the nine months ended September 30, 2026, selling and marketing expenses were $12,795,000, an increase of $1,481,000, or 13.1%, compared to $11,314,000 during the nine months ended September 30, 2025. This increase resulted primarily from higher commercial staffing levels following the commercial launch of CGuard Prime 135 cm in the U.S. in July 2025. The increase was partially offset by lower compensation and other personnel-related costs following the implementation of our Q3’26 Workforce Reduction, including a decrease in share-based compensation expense due primarily to the $1,100,000 reversal of share-based compensation expense associated with forfeited equity awards following the workforce reduction.

 

General and Administrative Expenses. For the nine months ended September 30, 2026, general and administrative expenses were $12,329,000, a decrease of $3,828,000, or 23.7%, compared to $16,157,000 during the nine months ended September 30, 2025. The decrease was primarily driven by lower compensation and personnel-related expenses, including the reversal of $280,000 of share-based compensation expense associated with forfeited equity awards following the Q3’26 Workforce Reduction and the inclusion in the prior-year period of severance and share-based compensation expenses of $575,000 and $1,554,000, respectively, associated with the departure of an executive.

 

Restructuring Expenses. For the nine months ended September 30, 2026, restructuring expenses were $1,074,000 compared with no restructuring expenses in the nine months ended September 30, 2025. The expenses primarily consisted of employee severance and related termination benefits associated with the workforce reduction initiative. See Note 6 to the condensed consolidated financial statements.

 

Financial Income. For the nine months ended September 30, 2026, financial income was $601,000, an increase of $96,000, or 19.0%, compared to $505,000 during the nine months ended September 30, 2025. The increase in financial income resulted primarily from lower financial expenses related to changes in exchange rates, partially offset by lower income from investments in marketable securities and money market funds.

 

7
 

 

Tax Expenses. We did not incur any tax expenses during the nine months ended September 30, 2026 and September 30, 2025.

 

Net Loss. For the nine months ended September 30, 2026, our net loss was $37,775,000, an increase of $750,000, or 2.0%, compared to $37,025,000 during the nine months ended September 30, 2025. The increase in net loss resulted primarily from a decrease in gross profit of $1,316,000, partially offset by a decrease in total operating expenses of $470,000 (including restructuring expenses of $1,074,000) and an increase in financial income of $96,000 compared to the prior-year period.

 

Liquidity and Capital Resources

 

We had an accumulated deficit as of September 30, 2026, of $340 million, as well as a net loss of $38 million for the nine months ended September 30, 2026, and negative operating cash flows. We expect to continue incurring losses and negative cash flows from operations until we expand our commercial revenue to a scale that funds our commercial resources, development activities and support functions. As a result of these expected losses and negative cash flows from operations, along with our current cash position, we believe we do not have sufficient resources to fund operations for at least the next 12 months from the date of issuance of the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q. Therefore, there is substantial doubt about our ability to continue as a going concern.

 

On November 16, 2026, we closed the November 2026 Offering (as defined below) resulting in gross proceeds of approximately $37.5 million, before deducting underwriting discounts and commissions and estimated offering expenses. For additional information, see “November 2026 Public Offering” below.

 

Our plans include continued commercialization of our products and raising capital through the sale of additional equity securities, debt financing, capital inflows from strategic partnerships and the exercise of outstanding warrants. There can be no assurance, however, that we will be successful in obtaining the level of financing needed for our operations. If we are unsuccessful in commercializing our products or raising capital, we may need to reduce, curtail or cease operations.

 

In May 2023, we closed a private placement offering that resulted in aggregate gross proceeds of approximately $42.2 million, before deducting fees payable to the placement agent and other offering expenses payable by us, pursuant to which we issued and sold 10,266,270 shares of our common stock, pre-funded warrants to purchase up to 15,561,894 shares of common stock and warrants to purchase up to an aggregate of 51,656,328 shares of common stock, consisting of Series H warrants to purchase up to 12,914,086 shares of common stock (the “Series H Warrants”), Series I warrants to purchase up to 12,914,078 shares of common stock (the “Series I Warrants”), Series J warrants to purchase up to 12,914,086 shares of common stock (the “Series J Warrants”) and Series K warrants to purchase up to 12,914,078 shares of common stock (the “Series K Warrants” and, together with the Series H Warrants, Series I Warrants and Series J Warrants, the “May 2023 Warrants”), at an offering price of $1.6327 per share of common stock and associated May 2023 Warrants and an offering price of $1.6326 per pre-funded warrant and associated May 2023 Warrants.

 

On September 21, 2026, we entered into amendments (the “Warrant Amendments”) with certain holders of outstanding May 2023 Warrants. Pursuant to the Warrant Amendments, we amended Series J Warrants to purchase up to 4,771,980 shares of common stock and Series K Warrants to purchase up to 9,543,947 shares of common stock to modify (i) the exercise price to $0.7674 per share and (ii) the termination date to 5:00 p.m. Eastern time on the earlier of (a) May 15, 2028 and (b) 20 trading days following our announcement of receipt of FDA approval of the CGuard Prime 80 cm. The Series J Warrants that were not amended, consisting of Series J Warrants to purchase up to 8,142,106 shares of common stock, have an exercise price of $1.3827 per share and a termination date of 5:00 p.m. Eastern time on the earlier of (a) May 15, 2028 and (b) 20 trading days after FDA approval of SwitchGuard NPS and the CGuard Prime 80 cm. The Series K Warrants that were not amended, consisting of Series K Warrants to purchase up to 3,370,131 shares of common stock, had an exercise price of $1.3827 per share and a termination date of 5:00 p.m. Eastern time on October 28, 2026, which was 20 trading days after the end of the fourth fiscal quarter following the commencement of first U.S. commercial sales of CGuard Prime 135 cm in July 2025 and expired unexercised on such date. The Series K Warrants that were amended pursuant to the Warrant Amendments and the Series J Warrants will expire on December 11, 2026, unless exercised prior to that date, which is 20 trading days after our announcement of receipt of the PMA for CGuard Prime 80 cm for use in TCAR procedures.

 

If the May 2023 Warrants, as amended, are exercised in cash in full, the aggregate gross proceeds would be approximately $57.9 million (of which approximately $35.7 million has been received as of the date of this Quarterly Report on Form 10-Q). There can be no assurance that we will achieve any of the remaining milestones set forth in the outstanding May 2023 Warrants or that the outstanding May 2023 Warrants will be exercised in cash in full. The last reported sale price of our common stock on November 13, 2026 was $0.64 per share. We believe that the likelihood that warrant holders will exercise their outstanding May 2023 Warrants, and therefore the amount of cash proceeds we would receive, is dependent upon the trading price of our common stock. If the trading price of our common stock is less than $1.3827 per share with respect to the May 2023 Warrants that were not amended or $0.7674 per share with respect to the May 2023 Warrants that were amended, we believe that warrant holders will be unlikely to exercise their outstanding May 2023 Warrants.

 

8
 

 

Following the announcement of the one-year follow-up results from our CGUARDIANS pivotal trial, the Series H Warrants were exercised in full for 292,996 shares of common stock and pre-funded warrants to purchase 12,621,090 shares of common stock. The net proceeds from the exercise of the Series H Warrants were $16.9 million after deducting placement agent fees.

 

Following the announcement of the FDA’s premarket approval of CGuard Prime, the Series I Warrants were exercised in full for 2,352,393 shares of common stock and pre-funded warrants to purchase 10,561,685 shares of common stock during June and July 2025. The net proceeds from the exercise of the Series I Warrants were $16.9 million after deducting placement agent fees.

 

In May 2024, we entered into an Equity Distribution Agreement (the “2024 Distribution Agreement”) with Piper Sandler & Co., as sales agent (“Piper Sandler”). Pursuant to the 2024 Distribution Agreement, we were able to offer and sell from time to time, at our option, through or to Piper Sandler shares of our common stock having an aggregate offering price of up to $75 million. We paid Piper Sandler a commission at a fixed rate of 3.0% of the aggregate gross proceeds from each sale of the shares under the 2024 Distribution Agreement. On April 3, 2026, we terminated the 2024 Distribution Agreement in connection with our entry into the 2026 Distribution Agreement (as defined below) with BTIG (as defined below). During the nine months ended September 30, 2026, we did not sell any shares pursuant to the 2024 Distribution Agreement.

 

In August 2025, we closed a private placement offering that resulted in aggregate gross proceeds of approximately $40.1 million, before deducting fees payable to the placement agent and other offering expenses payable by us.

 

In April 2026, we entered into an Equity Distribution Agreement (the “2026 Distribution Agreement”) with BTIG, LLC, as sales agent (“BTIG”). Pursuant to the 2026 Distribution Agreement, we may offer and sell from time to time, at our option, through or to BTIG shares of our common stock having an aggregate offering price of up to $75 million. We will pay BTIG a commission of up to 3.0% of the aggregate gross proceeds from each sale of the shares under the 2026 Distribution Agreement. As of the date of this Quarterly Report on Form 10-Q, we have not sold any shares pursuant to the 2026 Distribution Agreement.

 

November 2026 Public Offering

 

On November 13, 2026, we entered into an underwriting agreement (the “Underwriting Agreement”) with Lake Street Capital Markets, LLC, as representative (the “Representative”) of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale in an underwritten public offering (the “November 2026 Offering”) of (i) 7,342,308 shares of our common stock, and pre-funded warrants to purchase up to 50,350,000 shares of our common stock (the “November 2026 Pre-Funded Warrants”), and (ii) accompanying Series L warrants to purchase up to 43,269,231 shares of our common stock (or, at the election of the holder, November 2026 Pre-Funded Warrants to purchase up to an equal number of shares of our common stock in lieu thereof) (the “Series L Warrants” and, together with the November 2026 Pre-Funded Warrants, the “November 2026 Warrants”), representing 75% of the aggregate number of shares of common stock and November 2026 Pre-Funded Warrants sold in the November 2026 Offering. Each share of our common stock is being sold together with an accompanying Series L Warrant at a combined public offering price of $0.65, and each November 2026 Pre-Funded Warrant is being sold together with an accompanying Series L Warrant at a combined public offering price of $0.6499, which equals the combined public offering price per share of our common stock and accompanying Series L Warrant, minus $0.0001.

 

The November 2026 Offering closed on November 16, 2026. The gross proceeds from the November 2026 Offering were approximately $37.5 million, and we estimate that the gross proceeds from the November 2026 Offering will be approximately $43.1 million if the Representative exercises its option to purchase additional securities in full (as further described below), in each case, prior to deducting underwriting discounts and commissions and estimated offering expenses payable by us, and excluding the proceeds, if any, from the exercise of the Warrants.

 

Each Series L Warrant has an exercise price of $0.65 per share of our common stock, is immediately exercisable upon issuance, will expire one year from the date of issuance and may be exercised, at the holder’s election, for pre-funded warrants in lieu of shares of our common stock. If the Series L Warrants are exercised in cash in full, the aggregate gross proceeds would be approximately $28.1 million. There can be no assurance that the outstanding Series L Warrants will be exercised in cash in full.

 

Each November 2026 Pre-Funded Warrant has an exercise price of $0.0001 per share of our common stock, is immediately exercisable upon issuance and may be exercised at any time until exercised in full. A holder may not exercise any portion of its November 2026 Warrants to the extent that the holder, together with its affiliates and attribution parties, would beneficially own more than 4.99% (or, at the election of the holder, 9.99%) of our outstanding common stock immediately after exercise.

 

We also granted the Representative a 30-day option to purchase up to 8,653,846 additional shares of our common stock and/or pre-funded warrants to purchase up to 8,653,846 shares of our common stock and/or Series L Warrants to purchase up to 6,490,384 shares of our common stock (or pre-funded warrants in lieu thereof) (or any combination thereof) at the applicable public offering price minus underwriting discounts and commissions, representing 15% of the total number of shares of our common stock, November 2026 Pre-Funded Warrants and Series L Warrants sold in the November 2026 Offering, solely to cover over-allotment, if any. As of the date hereof, the Representative has not exercised this option, and there can be no assurance that the Representative will exercise the option, in whole or in part.

 

9
 

 

Nine months ended September 30, 2026, compared to the nine months ended September 30, 2025

 

General. As of September 30, 2026, we had cash and cash equivalents of $19,246,000 as compared to cash and cash equivalents of $8,939,000 and marketable securities of $45,272,000 as of December 31, 2025. We have historically met our cash needs through a combination of issuing new shares, borrowing activities and product sales. Our cash requirements are generally for research and development, marketing and sales activities, finance and administrative costs, capital expenditures and general working capital.

 

For the nine months ended September 30, 2026, net cash used in our operating activities increased by $8,102,000, or 31.5%, to $33,860,000, from $25,758,000 during the same period in 2025. The primary reasons for the increase in cash used in our operating activities were an increase of $6,660,000 in compensation costs paid during the nine months ended September 30, 2026 (from $17,843,000 in the nine months ended September 30, 2025 to $24,503,000 in the nine months ended September 30, 2026) and an increase of $4,041,000 in payments to vendors, clinical service providers and other professional service providers, partially offset by an increase of $2,455,000 in payments received from customers during the nine months ended September 30, 2026 (from $5,591,000 in the nine months ended September 30, 2025 to $8,046,000 during the nine months ended September 30, 2026).

 

Cash provided by our investing activities was $44,157,000 during the nine months ended September 30, 2026, compared to $14,575,000 during the nine months ended September 30, 2025. The primary reason for the increase in cash provided by our investing activities was the receipt of $45,000,000 in proceeds from matured marketable securities.

 

There was no cash provided by financing activities for the nine months ended September 30, 2026. Cash provided by financing activities for the nine months ended September 30, 2025 was $55,569,000. The sources of cash provided by financing activities during the nine months ended September 30, 2025 were approximately $38,714,000 of aggregate net proceeds from our private placement offering in August 2025 and sales of common stock under the 2024 Distribution Agreement, and $16,855,000 of proceeds from the exercise of Series I Warrants.

 

Off-Balance Sheet Arrangements

 

We have no off-balance sheet transactions, arrangements, obligations (including contingent obligations) or other relationships with unconsolidated entities or other persons that have, or may have, a material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

 

Factors That May Affect Future Operations

 

We believe that our future operating results will continue to be subject to quarterly variations based upon a wide variety of factors, including market acceptance of our products, the timing of the resumption of U.S. commercialization of CGuard Prime following the voluntary recall, the cyclical nature of the ordering patterns of our distributors, the timing of regulatory approvals, the implementation of various phases of our clinical trials, manufacturing efficiencies due to the learning curve of utilizing new materials and equipment and the costs or other consequences associated with any current or future product recall. Product recalls in particular have adversely affected and may continue to adversely affect our operating results through the direct costs of executing a recall, lost revenues resulting from the removal of affected products from the market and the interruption of sales during any remediation period, costs associated with redesigning and remanufacturing affected products, potential regulatory, litigation and other legal costs, and longer-term reputational harm that may reduce market acceptance of our current and future products. Our operating results could also be impacted by a weakening of the euro and a strengthening of the New Israeli Shekel (“NIS”), each against the U.S. dollar. Lastly, other economic conditions we cannot foresee may affect customer demand, such as individual country reimbursement policies pertaining to our products.

 

Contractual Obligations and Commitments

 

During the nine months ended September 30, 2026, there were no material changes to our contractual obligations and commitments since the year ended December 31, 2025.

 

Recently Adopted and Issued Accounting Pronouncements

 

See Note 3 to our condensed financial statements in Part I, Item 1 of this Quarterly Report on Form 10-Q.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

Not applicable.

 

Item 4. Controls and Procedures

 

Management’s Conclusions Regarding Effectiveness of Disclosure Controls and Procedures

 

As of September 30, 2026, we conducted an evaluation, under the supervision and participation of management including our chief executive officer and chief financial officer, of the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) of the Securities Exchange Act of 1934, as amended). There are inherent limitations to the effectiveness of any system of disclosure controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives.

 

Based upon this evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures are effective at the reasonable assurance level as of September 30, 2026.

 

Changes in Internal Control over Financial Reporting

 

There were no changes in our internal control over financial reporting during the fiscal quarter ended September 30, 2026, that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

10
 

 

PART II - OTHER INFORMATION

 

Item 1. Legal Proceedings

 

From time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. There are currently no pending material legal proceedings, and we are currently not aware of any legal proceedings or claims against us or our property that we believe will have any significant effect on our business, financial position or operating results.

 

Item 1A. Risk Factors

 

Except as set forth below in this Item 1A and the Risk Factors included in our previous filings made with the SEC, there have been no material changes to our risk factors from those disclosed in “Part I. Item 1A. Risk Factors” in the Form 10-K filed with the SEC on March 18, 2026.

 

Management has concluded that there is substantial doubt about our ability to continue as a going concern, and our condensed financial statements for the quarter ended September 30, 2026 includes an explanatory paragraph as to our ability to continue as a going concern, which could prevent us from obtaining new financing on reasonable terms or at all.

 

Because we have had recurring losses and negative cash flows from operating activities, substantial doubt exists regarding our ability to remain as a going concern at the same level at which we are currently performing. Accordingly, our condensed financial statements for the quarter ended September 30, 2026 includes an explanatory paragraph as to our potential inability to continue as a going concern. The doubts regarding our ability to continue as a going concern may adversely affect our ability to obtain new financing on reasonable terms or at all.

 

If we fail to comply with the continued listing requirements of the Nasdaq Capital Market, our common stock may be delisted and the price of our common stock and our ability to access the capital markets could be negatively impacted.

 

Nasdaq has established certain standards for the continued listing of a security on the Nasdaq Capital Market. The standards for continued listing include, among other things, that the minimum bid price for the listed securities not fall below $1.00 per share for a period of 30 consecutive trading days and that we maintain a minimum of $2,500,000 in stockholders’ equity.

 

On July 17, 2026, we received a notification letter, or the Notification Letter, from the Nasdaq Listing Qualifications notifying us that we are not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2), or the Rule, for continued listing on The Nasdaq Capital Market. The Notification Letter provides that we have 180 calendar days, or until January 13, 2027, to regain compliance with the Rule. To regain compliance, the bid price of our common stock must have a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. In the event we do not regain compliance by January 13, 2027, we may then be eligible for an additional 180 days if we meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice of our intention to cure the deficiency during the second compliance period. If we do not qualify for the second compliance period or fail to regain compliance during the second compliance period, then Nasdaq will notify us of its determination to delist our common stock, at which point we will have an opportunity to appeal the delisting determination to a Hearings Panel.

 

No assurance can be given that we will be able to regain compliance with the Rule. Failure to meet applicable Nasdaq continued listing standards could result in a delisting of our common stock. A delisting of our common stock from Nasdaq could materially reduce the liquidity of our common stock and result in a corresponding material reduction in the price of our common stock. In addition, delisting could harm our ability to raise capital through alternative financing sources on terms acceptable to us, or at all, and may result in the potential loss of confidence by investors, employees and fewer business development opportunities.

 

11
 

 

Although we have completed our restructuring and associated workforce reduction, the restructuring may not result in the anticipated savings or operational efficiencies, may result in total costs and expenses that are greater than expected, and may disrupt our business.

 

We recently completed a restructuring plan that included a reduction in our workforce. We incurred costs and expenses in connection with the restructuring, and we may continue to incur additional costs and expenses related to the restructuring. In addition, our restructuring activities may subject us to reputational risks and litigation risks and expenses. We may not realize, in full or in part, the anticipated benefits, savings and improvements in our cost structure from our restructuring efforts due to unforeseen difficulties, delays or unexpected costs. If we are unable to realize the expected operational efficiencies and cost savings from the restructuring, our operating results and financial condition would be adversely affected. In addition, to the extent we do not realize such anticipated operational efficiencies, we may need to undertake additional workforce reductions or restructuring activities in the future.

 

Furthermore, the effects of the restructuring may continue to be disruptive to our operations. For example, our workforce reductions could yield unanticipated consequences, such as attrition beyond planned staff reductions, increased difficulties in our day-to-day operations and reduced employee morale. The changes to our operations and the reduction in workforce may yield unintended consequences and costs, such as the loss of institutional knowledge and expertise, attrition beyond our intended reductions in force, and a reduction in morale among our remaining employees, all of which may have an adverse effect on our business, results of operations or financial condition. If employees who were not affected by the reductions in force seek alternative employment, this could result in our seeking contractor support at unplanned additional expense or harm our productivity. Any employee litigation related to the headcount reduction could be costly and prevent management from fully concentrating on the business.

 

The workforce reduction may adversely affect our ability to attract and retain qualified management, scientific, technical, and manufacturing personnel who are critical to our business. For example, the workforce reduction may negatively impact our regulatory, technical operations, and commercial functions, which could adversely affect our ability to successfully develop, and ultimately, commercialize our products. We may find that the workforce reduction makes it more difficult to pursue new opportunities and initiatives and may require us to hire qualified replacement personnel, resulting in additional costs and expenses. Our future financial performance and our ability to develop our products or additional assets will depend, in part, on our ability to effectively manage any future growth or restructuring, as the case may be. Our failure to successfully accomplish any of the above activities and goals may have a material adverse impact on our business, results of operations and financial condition.

 

Our products have been, and may in the future be, subject to product notifications, recalls, or voluntary market withdrawals that could harm our reputation, business and financial results.

 

After regulatory approval has been obtained for medical device products, the product and the manufacturer are subject to continual review, including the review of adverse events and clinical results that are reported after our products are made available to patients, and there can be no assurance that such approval will not be withdrawn or restricted. Regulators may also subject approvals to restrictions or conditions or impose post-approval obligations on the holders of these approvals, and the regulatory status of such products may be jeopardized if such obligations are not fulfilled. If post-approval studies are required, such studies may involve significant time and expense.

 

The manufacturing and marketing of medical devices involves an inherent risk that our products may prove to be defective and cause a health risk even after regulatory clearances have been obtained. The FDA and similar governmental authorities in other countries have the authority to require the recall of commercialized products in the event of material regulatory deficiencies or defects in design or manufacture. Medical devices may also be modified after regulatory clearance is obtained to such an extent that additional regulatory clearance is necessary before the device can be further marketed. In these events, we may voluntarily implement a recall or market withdrawal or may be required to do so by a regulatory authority. For example, in May 2026, we announced a voluntary recall in the U.S. of CGuard Prime 135 cm, initiated in consultation with the FDA. This decision followed our determination during controlled launch that the technical success of the delivery system had not met performance expectations. Such recall, and any recalls in the future, could result in significant current and future costs and other negative impacts associated with such recalls (including inventory write-off costs, refunds), loss of revenues, sales or customers, potential actions by regulators or other governmental entities, potential claims and lawsuits by customers and patients (including class action product liability litigation), other operational impacts and consequences such as business disruption, loss of personnel and distraction of management or other key employees, the restatement of previously issued financial statements, inability to raise capital, as well as negative publicity and damage to our reputation, which could have a material adverse impact on our business, results of operations and financial condition.

 

12
 

 

In the European Economic Area, we must comply with the medical device vigilance system under Regulation (EU) 2017/745 on medical devices, or the MDR. Under this system, manufacturers are generally required to report serious incidents involving medical devices via an electronic system incorporated into the EU database on medical devices, called EUDAMED. Furthermore, manufacturers are required to take Field Safety Corrective Actions (“FSCAs”) to reduce a risk of death or serious deterioration in the state of health associated with the use of a medical device that is already placed on the market. An FSCA may include the recall, modification, exchange, destruction or retrofitting of the device. FSCAs must be communicated by the manufacturer or its legal representative to its customers and/or to the end users of the device through Field Safety Notices. FSCAs must be reported to the relevant competent authorities, even if the FSCA was undertaken in a third country in relation to a device which is also legally made available on the Union market and the reason for the FSCA is not limited to the device made available in the third country.

 

Any adverse event involving our products could result in other future voluntary corrective actions, such as recalls or customer notifications, or agency action, such as inspection or enforcement action. Adverse events have been reported to us in the past, and we cannot guarantee that they will not occur in the future. Any corrective action, whether voluntary or involuntary, as well as defending ourselves in a lawsuit, would require the dedication of our time and capital, distract management from operating our business and could harm our reputation and financial results.

 

Defects or failures associated with our products have led to recalls, and could lead to additional recalls, safety alerts or litigation, as well as significant costs and negative publicity.

 

Our business is subject to significant risks associated with the manufacture, distribution and use of medical devices that are placed inside the human body, including the risk that patients may be severely injured by or even die from the misuse or malfunction of our products caused by design flaws or manufacturing defects. In addition, component failures, design defects, off-label uses or inadequate disclosure of product-related information could also result in an unsafe condition or the injury or death of a patient. These problems could lead to a recall or market withdrawal of, or issuance of a safety alert relating to, our products and could result in significant costs, negative publicity and adverse competitive pressure. For example, in May 2026, we announced a voluntary recall in the U.S. of CGuard Prime 135 cm, initiated in consultation with the FDA. This decision followed our determination during the controlled launch that the technical success of the delivery system had not met performance expectations. The circumstances giving rise to recalls are unpredictable, and any recalls of existing or future products increase the probability of inspection by, or additional scrutiny from, the FDA and could have a material adverse effect on our business, financial condition and results of operations.

 

The medical device industry has historically been subject to extensive litigation over product liability claims. Operating in the area of the neck with the brain as the end organ is dangerous and presents risks of adverse events such as bleeding, arterial dissection, cranial nerve injury, myocardial infarction, stroke and death, which subject us to a greater risk of being involved in litigation than companies with products used in less critical areas of the body. We may be subject to product liability claims if our products cause, or merely appear to have caused, an injury or death, even if due to physician error. In addition, an injury or death that is caused by the activities of our suppliers, such as those that provide us with components and materials, or by an aspect of a treatment used in combination with our products, such as a complementary drug or anesthesia, may be the basis for a claim against us by patients, hospitals, physicians or others purchasing or using our products, even if our products were not the actual cause of such injury or death. We may choose to settle any claims to avoid fault and complication, not due to failure of our products. An adverse outcome involving one of our products could result in reduced market acceptance and demand for all of our products and could harm our reputation and our ability to market our products in the future. In some circumstances, adverse events arising from or associated with the design, manufacture or marketing of our products could result in the suspension or delay of regulatory reviews of our premarket notifications or applications for marketing. Any of the foregoing problems could disrupt our business and have a material adverse effect on our business, financial condition and results of operations.

 

13
 

 

Although we carry product liability insurance in the United States and in other countries in which we conduct business, including for clinical trials and product marketing, we can give no assurance that such coverage will be available or adequate to satisfy any claims. Product liability insurance is expensive, subject to significant deductibles and exclusions, and may not be available on acceptable terms, if at all. If we are unable to obtain or maintain insurance at an acceptable cost or on acceptable terms with adequate coverage or otherwise protect against potential product liability claims, we could be exposed to significant liabilities. A product liability claim, recall or other claim with respect to uninsured liabilities or for amounts in excess of insured liabilities could have a material adverse effect on our business, financial condition and results of operations. Defending a suit, regardless of its merit or eventual outcome, could be costly, could divert management’s attention from our business and might result in adverse publicity, which could result in reduced acceptance of our products in the market, product recalls or market withdrawals.

 

We are required to file adverse event reports under MDR and regulations with the FDA, which reports are publicly available on the FDA’s website. We are required to file MDRs if our products may have caused or contributed to a serious injury or death or malfunctioned in a way that could likely cause or contribute to a serious injury or death if it were to recur. Any such MDR that reports a significant adverse event could result in negative publicity, which could harm our reputation and future sales.

 

Even if products we develop receive marketing approval, we or others may later discover that the product is less effective than previously believed or causes undesirable side effects that were not previously identified, which could compromise our ability or that of any collaborators to market the product, and could cause regulatory authorities to take certain regulatory actions, which could harm our commercial operations.

 

It is possible that our clinical trials may indicate an apparent positive effect of a product that is greater than the actual positive effect, if any, or alternatively fail to identify undesirable side effects. For example, we or others may discover that our products are less safe or effective than previously believed. If we or others discover that a product is less effective than previously believed or causes undesirable side effects that were not previously identified, any of the following adverse events could occur:

 

  ● regulatory authorities may withdraw their approval of the product or seize the product;
     
  ● we, or any of our collaborators, may be required to recall the product, change the way the product is administered or conduct additional clinical trials;

 

  ● additional restrictions may be imposed on the marketing of, or the manufacturing processes of, the particular product;
     
  ● we, or any of our collaborators, may be subject to fines, injunctions or the imposition of civil or criminal penalties;
     
  ● regulatory authorities may require the addition of labeling statements, such as a “black box” warning or a contraindication including with the product;
     
  ● we, or any of our collaborators, may be required to create a Medication Guide outlining the risks of the previously unidentified side effects for distribution to patients;
     
  ● we could be sued and held liable for harm caused to patients;
     
  ● physicians and patients may stop using our product; and
     
  ● our reputation may suffer.

 

Any of these events could harm our business and operations and could negatively impact our stock price.

 

For example, in May 2026, we announced a voluntary recall in the U.S. of CGuard Prime 135 cm, initiated in consultation with the FDA. This decision followed our determination during the controlled launch that the technical success of the delivery system had not met performance expectations. Such recall, and any recalls in the future, could result in significant current and future costs and other negative impacts associated with such recalls (including inventory write-off costs and refunds), loss of revenues, sales or customers, potential actions by regulators or other governmental entities, potential claims and lawsuits by customers and patients (including class action product liability litigation), other operational impacts and consequences such as business disruption, loss of personnel and distraction of management or other key employees, the restatement of previously issued financial statements, inability to raise capital, as well as negative publicity and damage to our reputation, which could have a material adverse impact on our business, results of operations and financial condition.

 

14
 

 

Material modifications to our products may require new 510(k) clearances, premarket approval, or CE Marks, or may require us to recall or cease marketing our products until new clearances or approvals are obtained.

 

Material modifications to the intended use or technological characteristics of our products will require new 510(k) clearances, premarket approvals (“PMA”) by the FDA or CE Marks under the EU Medical Device Regulation (“MDR”) prior to implementing the modifications, or require us to recall or cease marketing the modified devices until these clearances or approvals are obtained. Furthermore, changes to our manufacturing facility or supplier of components used in our products require prior FDA approval of a PMA supplement. The FDA requires device manufacturers to initially make and document a determination of whether or not a modification requires a new approval, supplement or clearance; however, the FDA can review a manufacturer’s decision. Any modification to an FDA cleared device that would significantly affect its safety or effectiveness or that would constitute a major change in its intended use would require a new 510(k) clearance or approval of a PMA supplement. We may not be able to obtain additional 510(k) clearances or premarket approvals for new products or for modifications to, or additional indications for, our products in a timely fashion, or at all. Delays in obtaining required future clearances would harm our ability to introduce new or enhanced products in a timely manner, which in turn would harm our future growth. We have made modifications to our products in the past that we believe do not require additional clearances or approvals, and we may make additional modifications in the future. If the FDA or an EU Notified Body disagrees and requires new clearances or approvals for any of these modifications, we may be required to recall and to stop selling or marketing our products as modified, which could harm our operating results and require us to redesign our products. In these circumstances, we may be subject to significant enforcement actions. In response to the voluntary recall in the U.S. of CGuard Prime 135 cm, initiated in consultation with the FDA in May 2026, we intend to implement design improvements to CGuard Prime 135 cm. However, there can be no assurance that such design improvements will be sufficient to obtain FDA approval, or that any such approval will be obtained in a timely manner, if at all.

 

We bear the risk of warranty claims on our products.

 

We may not be successful in claiming recovery under any warranty or indemnity provided to us by our suppliers or vendors in the event of a successful warranty claim against us by a customer, and any recovery from such supplier or vendor may not be adequate. Furthermore, we may not have any, or have an adequate, warranty provided by our supplier. In addition, warranty claims brought by our customers related to third-party components may arise after our ability to bring corresponding warranty claims against such suppliers expires, which could result in costs to us. In addition, we have been, and in the future could be, subject to costs related to product recalls, and we could incur significant costs to correct any defects, warranty claims or other problems. Any such events could adversely affect our business, financial condition and results of operations.

 

Changes to trade policy, including tariff and customs regulations, or failure to comply with such regulations may have an adverse effect on our reputation, business, financial condition and results of operations.

 

Changes in U.S. or international social, political, regulatory and economic conditions or in laws and policies governing trade, manufacturing, development and investment in the countries where we currently conduct our business could adversely affect our business, reputation, financial condition and results of operations. Changes or proposed changes in U.S. or other countries’ trade policies may result in restrictions and economic disincentives on international trade.

 

We currently manufacture, package and distribute all of our products, including CGuard Prime, which we commercially launched in the U.S. in July 2025 following FDA approval of the PMA in June 2025 and which is currently subject to the voluntary recall described above, at our own facility in Israel. To support our anticipated production growth following the commercialization of CGuard Prime, we have engaged Aptyx Interventional Systems (“Aptyx”) to expand our manufacturing capacity of CGuard Prime finished goods to full-scale production at its ISO Class 7 cleanroom facility in North Carolina. While we are in the process of establishing manufacturing operations in the U.S. with Aptyx, this transition will take time, and until it is operational, we expect to rely entirely on product shipments from Israel to the U.S. market.

 

15
 

 

The U.S. government has recently adopted, proposed and considered a variety of tariff measures and other trade restrictions affecting imports from numerous countries, and additional changes to U.S. trade policy remain under active consideration. The implementation, modification, suspension, expiration, extension or judicial review of existing or proposed tariffs and trade measures has created and may continue to create significant uncertainty for companies engaged in international manufacturing and cross-border commerce. In addition, new investigations under U.S. trade laws, changes to customs rules, import restrictions, sanctions or other trade-related measures could result in additional duties, restrictions or compliance obligations affecting imported products and components.

 

Because we currently manufacture our products in Israel and remain dependent on shipments from Israel to serve the U.S. market while we continue efforts to expand manufacturing capacity in the United States, changes in tariffs, customs duties, import regulations or other trade measures applicable to products imported into the United States could increase our costs, reduce our margins, disrupt our supply chain, adversely affect customer demand or require us to modify our manufacturing, sourcing or distribution strategies. We cannot predict the scope, duration or outcome of current or future trade actions, related legal challenges, or any retaliatory measures by affected countries. Any of these developments could have a material adverse effect on our business, financial condition and results of operations.

 

Tariffs, economic sanctions and other changes in U.S. trade policy have in the past and could in the future trigger retaliatory actions by affected countries, and certain foreign governments have instituted or are considering imposing retaliatory measures on certain U.S. goods. Further, any emerging protectionist or nationalist trends (whether regulatory- or consumer-driven) either in the United States or in other countries could affect the trade environment. Our business, like many other corporations, would be impacted by changes to the trade policies of the United States and foreign countries (including governmental action related to tariffs, international trade agreements, or economic sanctions). We cannot predict whether, and to what extent, trade policies will change in the future. If tariffs or other trade restrictions are imposed on products manufactured in Israel while we remain dependent on Israeli manufacturing, our cost of goods sold for the U.S. market may increase materially, which could negatively impact our gross margins and limit our pricing flexibility. Additionally, changes to trade agreements or customs regulations between the U.S. and Israel could increase lead times, introduce logistical complexities, or require modifications to our supply chain planning. These or similar trade-related developments may have a material adverse effect on our business, financial condition, and results of operations.

 

If there are significant shifts in the political, economic and military conditions in Israel and its neighbors, it could have a material adverse effect on our business operations and ability to reach profitability.

 

Although we are incorporated in the State of Delaware and our headquarters are in Miami, Florida, our current manufacturing facility, certain of our key personnel and one of our offices are located in Israel. Our business is directly affected by the political, economic and military conditions in Israel and its neighbors. Since the establishment of the State of Israel in 1948, a number of armed conflicts have occurred between Israel and its neighboring countries and terrorist organizations active in the region, including Iran, Hamas (an Islamist terrorist militia and political group that controls the Gaza Strip), Hezbollah (an Islamist terrorist militia and political group based in Lebanon) and other terrorist organizations active in the region. These conflicts have involved missile strikes, hostile infiltrations and terrorism against civilian targets in various parts of Israel, which have negatively affected business conditions in Israel.

 

In recent years, Israel has been engaged in sporadic armed conflicts with Hamas in the Gaza Strip, with Hezbollah, an Islamist terrorist group that controls large portions of southern Lebanon, and with Iranian-backed military forces in Syria. In addition, Iran has threatened to attack Israel and may be developing nuclear weapons. Iran is also believed to have a strong influence among extremist groups in the region, such as Hamas in Gaza, Hezbollah in Lebanon, the Houthi movement in Yemen and various rebel militia groups in Syria and Iraq. On October 7, 2023, Hamas launched a series of attacks on civilian and military targets in southern and central Israel, to which the Israel Defense Forces responded. On October 9, 2025, Israel, Hamas, the United States and other countries in the region agreed to a framework for a ceasefire in Gaza between Israel and Hamas.

 

In addition, both Hezbollah and the Houthi movement attacked military and civilian targets in Israel, to which Israel responded, including through increased air and ground operations in Lebanon. In addition, the Houthi movement attacked international shipping lanes in the Red Sea, to which both Israel and the United States responded. While a ceasefire was brokered between Israel and Hezbollah in November 2024, in March 2026, hostilities resumed along Israel’s northern border with Lebanon, when Hezbollah resumed its attacks as part of a broader regional escalation. In response, Israel resumed military operations against Hezbollah in Lebanon.

 

16
 

 

Further, in April 2024 and October 2024, Iran launched a series of drone and missile strikes against Israel, to which Israel responded. In addition, in response to ongoing Iranian aggression and support of proxy attacks against Israel, on June 13, 2025, Israel conducted a series of preemptive defensive air strikes in Iran targeting Iran’s nuclear program and military commanders. While a ceasefire was reached in June 2025 following 12 days of hostilities, on February 28, 2026, the United States and Israel launched coordinated military strikes against Iran, including attacks on strategic military infrastructure and leadership targets, with the stated aim of degrading Iran’s capacity to conduct or support hostile operations against them. In response, Iran has fired missiles and drones toward population centers and military installations in Israel, Europe and neighboring countries in the Gulf region, and also launched counter-strikes against U.S. forces and allied bases throughout the Gulf region. Although the United States and Iran have announced ceasefire and de-escalation arrangements from time to time, including a memorandum of understanding entered into on June 17, 2026 that contemplates the termination of military operations on multiple fronts, hostilities have resumed and may continue or escalate. A broader regional conflict involving additional state and non-state actors remains a significant risk. The duration and severity of the conflicts in Gaza, northern Israel, Lebanon, Iran and the broader region are unknown at this time, and any renewed or continued clash among Israel, Hamas, Hezbollah, Iran or other countries or militant groups in the region may escalate in the future into a greater regional conflict. Continued military escalation, retaliatory actions, or broader regional involvement may adversely affect economic conditions, disrupt markets, and create uncertainty that could negatively impact our business, financial condition and results of operations.

 

Certain of our employees may be obligated to perform military reserve duty generally until they reach the age of 40 (or older, for officers or other citizens who hold certain positions in the Israeli armed forces reserves) and, in the event of a military conflict, may be called to active duty. In response to increases in terrorist activity and military conflicts in Israel, there have been periods of significant call-ups of military reservists. Military service call-ups that result in absences of personnel from us for an extended period of time may materially and adversely affect our business, prospects, financial condition and results of operations.

 

To date, our operations have not been adversely affected by this situation. We currently manufacture our CGuard EPS and CGuard Prime at our facility in Tel Aviv, Israel. If there were a disruption to our existing manufacturing facility or our ability to procure raw materials and ship our products, we would have no other means of manufacturing and distributing CGuard EPS or CGuard Prime until we were able to restore the manufacturing and distribution capability at our facility or develop alternative manufacturing facilities and distribution capabilities. However, the intensity and duration of the security situation in Israel have been difficult to predict, as are the economic implications on our business and operations and on Israel’s economy in general. If the current conflicts continue for a long period of time or expand to other fronts, our operations may be harmed.

 

Our commercial insurance does not cover losses that may occur as a result of events associated with war and terrorism. Although the Israeli government currently covers the reinstatement value of direct damages that are caused by terrorist attacks or acts of war, we cannot assure you that this government coverage will be maintained or that it will sufficiently cover our potential damages. Any losses or damages incurred by us could have a material adverse effect on our business. Any armed conflicts or political instability in the region would likely negatively affect business conditions and could harm our results of operations.

 

The continued political instability and hostilities between Israel and its neighbors and any future armed conflict, terrorist activity or political instability in the region could adversely affect our operations in Israel and adversely affect the market price of our shares of common stock. In addition, several organizations and countries may restrict doing business with Israel and Israeli companies have been and are today subjected to economic boycotts. The interruption or curtailment of trade between Israel and its present trading partners could adversely affect our business, financial condition and results of operations.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

None.

 

Item 3. Defaults Upon Senior Securities

 

None.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

17
 

 

Item 5. Other Information

 

During the quarter ended September 30, 2026, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement” (in each case, as defined in Item 408 of Regulation S-K).

 

Item 6. Exhibits

 

EXHIBIT INDEX

 

Exhibit No.   Description
     
3.1   Amended and Restated Certificate of Incorporation, as amended through September 30, 2015 (incorporated by reference to Exhibit 3.1 to Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2015)
     
3.2   Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to Current Report on Form 8-K filed with the Securities and Exchange Commission on June 29, 2021)
     
3.3   Certificate of Amendment to Amended and Restated Certificate of Incorporation of InspireMD, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on May 25, 2016)
     
3.4   Certificate of Amendment to Amended and Restated Certificate of Incorporation of InspireMD, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on September 29, 2016)
     
3.5   Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on March 15, 2017)
     
3.6   Certificate of Amendment to Certificate of Designation of Preferences, Rights and Limitation of Series C Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on November 29, 2017)
     
3.7   Certificate of Amendment to Certificate of Designation of Preferences, Rights and Limitation of Series B Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on December 12, 2017)
     
3.8   Certificate of Amendment to Amended and Restated Certificate of Incorporation of InspireMD, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on February 7, 2018)
     
3.9   Certificate of Amendment to Amended and Restated Certificate of Incorporation of InspireMD, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on March 28, 2019)
     
3.10   Certificate of Amendment to Amended and Restated Certificate of Incorporation of InspireMD, Inc. (incorporated by reference to Exhibit 3.17 to the Quarterly Report on Form 10-Q filed on May 10, 2021)
     
3.11   Certificate of Amendment to Amended and Restated Certificate of Incorporation of InspireMD, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on September 13, 2023)
     
3.12   Certificate of Amendment to Amended and Restated Certificate of Incorporation of InspireMD, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on June 3, 2026)
     
31.1*   Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
31.2*   Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
32.1*   Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
32.2*   Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
101.INS*   Inline XBRL Instance Document (the Instance Document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document)
     
101.SCH*   Inline XBRL Taxonomy Extension Schema Document
     
101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase Document
     
101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase Document
     
101.LAB*   Inline XBRL Taxonomy Extension Labels Linkbase Document
     
101.PRE*   Inline XBRL Taxonomy Extension Presentation Linkbase Document
     
104*   Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)

 

* Filed herewith.

 

18
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  INSPIREMD, INC.
     
Date: November 16, 2026 By: /s/ Marvin Slosman
  Name: Marvin Slosman
  Title:

President and Chief Executive Officer

(Principal Executive Officer)

     
Date: November 16, 2026 By: /s/ Michael Lawless
  Name: Michael Lawless
  Title:

Chief Financial Officer

(Principal Financial and Accounting Officer)

 

19

Keep reading